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6 Preface 
Malignant mesothelioma (MM) is a highly aggressive neoplasm caused by neoplastic 
transformation of mesothelial cells that line the body’s serous cavities and the internal 
organs. In the majority of patients mesothelioma is localized within the pleural cavity. At 
this moment, no curative medical procedures are available. With median survival of 9 to 
12 month after first signs of illness, the prognosis is poor. 
Mesothelioma is strongly associated with the exposure to airborne asbestos particles. 
Although the relation between exposure to asbestos and the occurrence of disease was 
already reported by the ancient Greek geographer Strabo and the roman naturist Gaius 
Plinius Secundus in 23 AD*, the first scientific report was published in the 1960’s by 
Wagner et al. (1). He reported a strong correlation between exposure to asbestos and 
the occurrence of mesothelioma, among asbestos-mine-workers in South-African’s Cape 
Province. Studies of Stumphius et al. noticed an increased incidence in mesothelioma 
cases among shipyard-workers in the “Royal Schelde” shipyard (2). 
Even though it became more distinct that asbestos exposure was one of the main causes 
for mesothelioma, the commercial use of asbestos peaked during the seventies. Tons 
of asbestos-containing materials are still present in buildings, ships and infrastructures. 
Production and usage of asbestos-containing material maintained in the Netherlands till 
the interdiction of asbestos-use in 1993. As millions of people were exposed to carcinogenic 
fibres, with accompanying serious health risks undisputed there is a responsibility for 
governments to support mesothelioma research. The United Kingdom’s Ministry of Justice 
has recently announced that the U.K. government is obligated to address the medical 
aspects of mesothelioma **. 
It is a misconception that with the ban of asbestos-use, the occurrence of mesothelioma 
will disappear within the following decades. Many people world wide are incidentally 
exposed to asbestos fibres. During the collapse of the New York World Trade Centre in 
2001 the citizens of New York not only faced the tragedy of a terrorist attack, but as a 
consequence thousands of people were exposed to a dust-cloud containing 400 tons of 
asbestos fibres (4% of all fibres within the dust-cloud). Soon after 9/11 the Mesothelioma 
Applied Research Foundation (MARF) was established to fund research, investigating new 
treatment strategies to cure mesothelioma. 
Figure 1: Demonstration of ships at Alang India by unprotected workers (left), asbestos industry in India 
and protest against importation of asbestos from Canada (right) (photo’s E. Burtynski (left) and Hazards 
Compaign)   
7Asbestos is a well known carcinogen to most people in western countries, however this does 
not apply to people in developing countries. As the western world tries to ban asbestos, the 
utilisation in Asian countries, especially India, is growing (3). Asbestos is collected in ship 
breaking yards in Alang India from western ships that contain high amount of asbestos-
containing material, making these ships to expensive to dismantle in developed countries 
(due to high costs of safety measurements). After grinding the asbestos-containing 
materials, the asbestos fibres are remodelled into asbestos-cement and corrugated roof-
plates (Figure 1). Besides the extraction of asbestos from ships, asbestos is also imported 
on large scale by Asian countries from Canada *** . The Canadian government funds an 
industry lobby group, the Chrysotile Institute, which promotes the “controlled use” of 
chrysotile asbestos in developing countries. The distribution of chrysotile asbestos is still 
possible, since chrysotile asbestos was not mentioned in the Rotterdam Convention in 
the 1980’s. The Rotterdam Convention did reject the use of all other types of asbestos, in 
their effort to ban toxic agents for health or environmental reasons. At that time is was a 
misapprehension that chrysotile is less carcinogenic, since chrysotile can be cleared from 
the lungs more easily. Despite the opposition of the world health organisation (WHO), 
Canada increased its asbestos mining activities and exported more asbestos last year (4). 
With the increased production, the total production is similar to the peak period in the 
sixties. Besides Canada, Russia, China and Kazakhstan are also mining for asbestos. 
In the absence of official actions the use of asbestos is increasing in large parts of the world. 
In 2006, Greenpeace successfully prevented the dumping of warships containing tonnes 
of asbestos by making the France public aware of these activities by their government. 
Growing concerns are reported by public health experts and the WHO (3, 5). Although 
the awareness from western communities is rising, stopping the export of asbestos and 
asbestos-containing material to third-world countries is still problematic, since there are 
economical interests involved. It’s becoming more distinct that the ban of asbestos did 
not solve but only transferred the problem to third-world countries. An underestimated 
number of 90.000 people die of asbestos-related diseases each year and the incidence is 
still rising.
* R.C. Barbalace, 1995-10-22; Environmentalchemistry.com; “History of Asbestos” 
** Ministry of Justice U.K., 27-10-02 ; Government announces meassures on asbestos-related illness 
*** D. Allen & L. Kazan-Allen; www.ibasecretariat.org; India’s asbestos time bomb
(ref 1-5 are included in the reference list of Chapter 1)
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CHAPTER 1: Tumour-induced immune suppression and immunotherapy 
Cancer is a major worldwide health problem and one of the most important causes of 
morbidity and mortality. Cancer is a disease which is characterized by abnormal proliferation 
of genetically altered cells, which typically invade other tissues and can spread to other 
parts of the body (metastasize). Defects in regulatory circuits that govern normal cell 
proliferation and homeostasis can occur in different cell types leading to distinct kinds 
of cancer. Changes in the genome, causing abnormal proliferation, are influenced by 
environmental factors and genetic-predispositions.
 Progress in cancer treatment using current treatment strategies (e.g. surgery, 
chemotherapy, radiotherapy, or combinations of these) has been made in the last 
decades. However, most cancers are still difficult to treat because in many cases the 
cancer recurrences. Also, these treatments can cause major late-onset morbidity and 
even mortality for instance due to cardiovascular diseases or an increased rate of 
secondary malignancies. Therefore, researchers are focussing on new approaches to 
develop treatments to increase cure rates, and which are more tumour-specific with fewer 
side effects. One of the approaches, which recently gained a lot of interest, is cancer 
immunotherapy. It attempts to harness the exquisite power and specificity of the immune 
system to recognize and to fight tumour cells. As scientific knowledge increases, it is 
becoming more evident that during tumour progression there is a constant interaction 
between the immune system and the developing tumour. While some immune cells are 
trying to bring tumour growth to a hold, other cells of the immune system are favouring 
tumour progression. This thesis reports on investigations to improve the effectiveness of 
immunotherapy approaches by targeting tumour escape mechanisms.
1.1. The hallmarks of cancer
In 2000, Hanahan and Weinberg described six essential alterations in normal cell 
physiology, which together define the prognosis of most human malignancies (1). Although 
the pathways that cells undertake on their way to transform to malignant cells are highly 
variable, it is well established that during this process several mutations in onco-genes 
and tumour suppressor genes take place (2-3). Mutations in these genes are essential 
in the acquisition or loss of biological capabilities. These mutations can occur at different 
time points during tumour progression and differ between tumour types. Once formed, 
all cancer types are composed of a complex mixture of various cell types; including 
tumour cells, immune cells and stromal cells; that collaborate to create malignant growth. 
Extensive investigations are elucidating the complexity of these different cell types that 
exist symbiotically with the tumour cells. Genetic and epigenetic alterations of tumour 
cells are eventually reflected in biological properties of cancer; that are common in all 
types of cancer (1, 4). These characteristics in tumour biology led to the description 
of six essential alterations in cell physiology that collectively dictate malignant growth; 
including 1: self-sufficiency in growth signals, 2: insensitivity to growth inhibitory (anti-
growth) signals, 3: tissue invasion and metastasis, 4: unlimited replicative potential, 5: 
sustained angiogenesis, and 6: evading programmed cell death (apoptosis). Recently, 
cancer-related inflammation is recognized as the seventh hallmark [7] (5-6) (Figure 1). 
These will be briefly discussed in the next part.
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Figure 1 A) In 2000, Hanahan described the six hallmarks of cancer. Recently a seventh hallmark, the 
inflammatory micro-environment was recognized as a important hallmark of cancer progression. B) Infiltration 
of inflammatory cells into tumour tissue is frequently observed in several types of cancer: cytokeratine 19 
expression on mesothelioma cells (red) with infiltrating inflammatory cells at the rim of the tumour (*).
Self-sufficiency in growth signals: Normal cells require growth signals for proliferation. 1. 
Commonly, these stimuli are produced by one cell type in order to stimulate proliferation 
of another. However, in cancer cells, signalling molecules are over-expressed and 
growth-stimulating signals are amplified. Thus tumour cells acquire the ability to 
synthesize growth factors to which they are responsive, promoting uncontrolled 
division and cell growth (7). 
Insensitivity to growth inhibitory signals: In normal tissue, multiple anti-proliferative 2. 
signals exist to maintain cell quiescence and tissue homeostasis, however cancer cells 
become insensitive to such anti-growth signals and maintain replicative capacities 
(6).
Tissue invasion and metastasis: Growth of a tumour can lead to invasion of surrounding 3. 
tissue or to metastasis to other tissues in the body. In order for cancer to spread, cells 
must acquire mutations that turn on genes which allow them to break free from the 
primary tumour and travel to other sites in the body. Metastatic growth is the cause 
of death in 90% of all human cancers (8).
Unlimited replicative potential: Replication without limitation requires maintenance 4. 
of the chromosomal ends, known as telomeres. As cells divide, telomere length is 
reduced. Tumour cell can overcome this limitation by up regulating expression of 
telomerase enzymes (9). Thereby cells can keep their telomeres of the chromosomal 
ends above a critical threshold, making them capable of unlimited multiplication. In 
addition, fusion of chromosomes ends is frequently observed in cancer cells, which 
also facilitates multiplication without limitations (10)
Sustained angiogenesis: Blood supply is a vital process in the progression of cancer 5. 
from small, localized neoplasms to larger growing tumors. The expression of growth 
factors that recruit new vasculature from existing blood vessels is essential to fuel 
continued growth and division (11). 
Evading programmed cell death (apoptosis): Normal cells that accumulate excessive 6. 
DNA damage undergo apoptosis. However, cancer cells are resistant to apoptosis, 
and thus they continue to grow and divide even as they accumulate mutations (12-
15). 
Cancer-related inflammation: Epidemiological studies have revealed that chronic 7. 
inflammation predisposes for certain forms of cancer. Increasing evidence indicates 
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that the “inflammation-cancer” connection is not only restricted to the initiation of 
cancer process, since all types of cancer appear to have an inflammatory component 
in their microenvironment. Therefore, inflammation seems a critical component of 
tumour progression (6, 16-17). Recent reports have shed new light on the molecular 
and cellular mechanisms linking cancer and inflammation (18-19). Two pathways 
have been identified. First, the intrinsic pathway leads to activation of different classes 
of oncogenes driving cells to express inflammation-related mediators that guide the 
formation of the inflammatory tumour microenvironment. Secondly, in the extrinsic 
pathway, the inflammatory conditions facilitate tumour growth. To understand these 
relations, physiological interactions between the immune system and tumour cells 
need to be discussed.
1.2. Tumour-immunosurveillance 
By using murine tumour transplantation-models, Llyod Old, George Klein, and others 
showed that the immune system of healthy recipient mice was able to detect the 
transformed malignant cells and differentiate them from normal cells (20-21). The concept 
that nascent transformed cells could be detected by the immune system was embodied 
in the cancer immunosurveillance hypothesis by Frank MacFarlane Burnet and Lewis 
Thomas in 1957; “it is by no means inconceivable that small accumulations of tumour 
cells may develop and because of their possession of new antigenic potentialities provoke 
an effective immunological reaction with regression of the tumour and no clinical hint of 
its existence” (22). At that time the hypothesis was very controversial, however recently 
it’s becoming more and more evident that the immune system plays a crucial role in host 
prevention against cancer.
 Tumour-associated antigens (TAA) are antigens acquired by a tumour cell in the process 
of neoplastic transformation that can elicit a specific immune response by the host. 
Expression of these antigens is caused by mutations leading to synthesis and overexpression 
of abnormal proteins. The immune system can discriminate between malignant cells and 
their normal counterparts through recognition of these TAA expressed by tumour cells.
 It is known that several immunological cells are involved in the recognition and 
destruction of tumours during early stages of development. These include cells and 
factors of the innate and adaptive immune system (23-25). Cells that play a role during 
the early reaction of the immune system (innate immunity / naive immunity) provide 
the early lines of defence against pathogens and abnormal cell growth. Macrophages, 
neutrophils, complement components, dg T cells, natural killer (NK) cells, NKT cells and 
certain cytokines (IL-12, IFN-g) participate in the innate immune mechanisms protecting 
against cancer. For example, NK cells can prevent the development of tumours by their 
ability to produce perforin, leading to the induction of cell death (26-27). 
In contrast to the innate immune reaction, cells of the adaptive (specific immunity) 
phase of the immune reaction have adapted a response to certain antigens. To generate 
a specific immune response against cancer cells, TAA need to be presented to the cells 
of the adaptive immune system. Dendritic cells (DCs) play an important role in the 
activation and modulation of lymphocyte subsets in the adaptive immune system (28-
29). DCs are widely acknowledged for their antigen presenting capacity. These antigen 
presenting cells (APCs) originate from bone marrow precursor cells and are found at 
low frequencies in peripheral tissues where they maintain an immature phenotype and 
search their surroundings for foreign substances. When tumour cells die, TAA are set 
free. These TAA can be taken up by antigen presenting cells. After taken up of these 
antigens, the DCs mature and migrate to regional draining lymphoid organs. The captured 
antigen is processed by major histocompatibility complex (MHC) molecules of DCs and 
induce antigen-specific activation of lymphocytes. B lymphocytes are capable of producing 
antibodies, functioning as mediators of the humoral immunity. For example, antibodies can 
bind tumour cells and assist in their elimination via various mechanisms like enhancing 
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phagocytosis (opsonisation). Tumour-specific T lymphocytes mediate the cellular immunity. 
T lymphocytes consist of functionally distinct populations, the best defined of which are 
helper T cells (Th cells) and cytotoxic T lymphocytes (CTL). In the response to antigen, 
Th cells stimulate proliferation and differentiation of B and T cells (and others). CTL are 
capable of killing cells that express foreign antigens. 
After activation by dendritic cells in the lymphoid organs, B and T lymphocytes accumulate 
and enter the circulation. In the elimination of tumours, tumour-specific CTL play a 
dominant role. CTL can infiltrate and kill tumour cells after recognition of TAA.
1.3. Tumour immune escape 
Increasing evidence reveals that when tumour progress in time, tumour cells undergo 
changes to escape immune surveillance. To account for this, the concept of immune 
surveillance was refined to a process called “cancer immunoediting” (23). The process 
encompasses three phases: Elimination, Equilibrium, and Escape. During the first phase, 
immune surveillance takes place. However, tumour cells that are not eliminated by the 
immune system can enter the equilibrium state, in which there is an equilibrium between 
tumour growth and tumour killing by cells of the immune system. In this stage, tumours 
can persist for years without progressing to more severe tumour stages. However, during 
this period, tumour cells may further accumulate mutations; potentially generating 
variants that can escape the immune system, by either evading the induction of an immune 
response or the inhibition of anti-tumour responses via a variety of mechanisms. Some of 
these mechanisms are related to the tumour cells, whereas others act via the attraction 
and interaction with infiltrating immune cells.
Decreased expression of MHC class I molecules leads to decreased TAA presentation 1. 
to T cells. Downregulation of MHC molecule expression makes tumour cells less 
recognizable for cytotoxic T cells.
Tumour cells can also lose the expression of TAA that elicit an immune response. 2. 
If these antigens are not required for growth of the tumour or maintenance of the 
transformed phenotype, the antigen-negative tumour cells have a growth advantage 
in the host.
Cell surface antigens on tumour cells can also be hidden from the immune system by 3. 
glycocalyx molecules, such as sialic acid-containing mucopolysaccharides.
By the production of immune suppressive substances such as vascular endothelial 4. 
growth factor (VEGF), interleukin 10 and 23 (IL-10, IL-23) and transforming growth 
factor beta (TGF-b), tumour cells can directly affect the function of DCs and T cells within 
the tumour microenvironment. In addition, tumour cells can also exploit mechanisms 
leading to the abolishment of the induced anti-tumour response. Several tumour types 
express programmed death ligand-1 (PD-L1) which inhibits T cells through interaction 
with the negative co-stimulatory receptor, PD-1 (30). Some malignancies may also 
employ nutrient catabolism to establish tolerance by depriving effector T cells of the 
necessary nutrients to mount a robust immune response. For example, many tumour 
tissues have an increased expression of indoleamine 2,3-dioxygenase (IDO), which 
catalyzes the essential amino acid tryptophan, arresting T cells in the G1 phase, and 
thereby providing immune escape (31).
Tumour cells may also induce specific immunologic tolerance. Tolerance may occur 5. 
because tumour cells present TAA in a tolerogenic form to lymphocytes.
1.4. Immune suppressive mechanisms
Another important escape mechanism how tumours can resist immune destruction is the 
induction of an immunesuppressive microenvironment. In the tumour microenvironment, 
inflammatory cells and molecules influence almost every aspect of the cancer progress. For 
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example, specialized white blood cells (M2 type macrophages [TAM] and myeloid derived 
suppressor cells [MDSC], see below) in the tumour environment assist the malignant 
behaviour of tumour cells, not just by producing cytokines, but also by secreting growth 
factors and matrix-degrading enzymes. These matrix-degrading enzymes can mobilize the 
cytokines (e.g. IL-1b, IL-6) and growth factors (e.g. VEGF) from the extracellular matrix 
which promote tumour progression or enhance metastasis. These cells can also act directly 
on tumour cells, endothelial cells and on antigen-specific T cells. Furthermore, tumour 
tissue, peripheral blood and lymph nodes contain significant amounts of regulatory T 
lymphocytes (Tregs), capable of suppressing the effector arm in anti-tumoural responses. 
It is evident that immune cells can either protect the host against cancer development or 
promote the emergence of tumours with reduced immunogenicity leading to a complex 
interplay of tumour growth and tumour regression mechanisms (17). In the next sections, 
three types of immune suppressive cells are discussed; myeloid derived suppressor cells 
(MDSC), tumour-associated macrophages (TAMs) and regulatory T cells (Tregs). These 
cells can blunt the immune response against cancer and inhibit the effect of therapeutic 
approaches. Therefore, targeting the immune suppressive microenvironment is proposed 
as a strategy to improve and refine novel therapies (4, 17) (Figure 2).
A           B
 
Figure 2 A) Tumours escape immune surveillance by avoiding recognition by the immune system via 
distinct mechanisms (left part) or by inhibiting anti-tumour responses via the induction of a suppressive 
microenvironment. B) Within this environment there are three immune cell types abundantly present; 
myeloid-derived suppressor cells (MDSC), tumour-associated macrophages (TAMs) and regulatory T cells.
1.5. Myeloid-derived suppressor cells
1.5.1. Identification of MDSC
Myeloid-derived suppressor cells (MDSC) were first described by Bronte and Gabrilovich 
in 2000/2001 (32-33). MDSC are a heterogeneous population of bone marrow derived 
myeloid cells (thus include both mature and immature/precursor phenotypes), comprising 
of immature monocytes/macrophages, granulocytes, and DCs at different stages of 
differentiation and expressing a number of surface markers with immunosuppressive 
functions (34). To prevent confusion in the field, the previous terms of ‘myeloid suppressor 
cells (MSC)’ or ‘immature myeloid cells (iMC)’ are nowadays replaced by MDSC (34).
 Accumulation of these cells has been reported under pathologic conditions, including 
cancer, various infectious diseases, sepsis, trauma, bone marrow transplantation and some 
autoimmune disorders. In pathological conditions, a partial block in the differentiation 
from immature myeloid cells to mature myeloid cells results in the expansion of this 
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population. Factors released in blood from affected tissue, promote the expansion of MDSC 
through stimulation of myelopoiesis and inhibition of the differentiation towards mature 
myeloid cells (35). Although recent publications clearly demonstrate that the expansion 
of an immunosuppressive MDSC population is frequently observed in many pathological 
conditions, most of the attention has been focused on the role of these cells in cancer 
(33-42). Up to a tenfold increase in MDSC numbers were detected in the blood of patients 
with different types of cancer and in many murine-tumour models, as many as 20–40% of 
nucleated splenocytes are MDSC (35).  
 MDSC are characterized by the expression of immature markers and myeloid markers. 
Most importantly, these cells possess a high potential to suppress immune responses in 
vitro and in vivo (34). MDSC can upregulate genes related to the metabolism of amino 
acids (L-arginine), production of reactive oxygen species (ROS) and nitrogen species 
(NOS), as well as upregulation of immune suppressive surface molecules. How this 
influences immune responses is discussed in 1.5.3. More recently, subsets of MDSC have 
been identified within the heterogeneous group of immature myeloid cells. Two major 
groups of MDSC were recognized based on their morphology, the intensity of surface 
marker expression and cell metabolism (36-38). Poly-morph nuclear (PMN)-MDSC are 
phenotypically granulocyte-like, whereas mononuclear (MO)-MDSC are phenotypically 
monocyte-like. In mice both MDSC types express the markers: CD11b, Gr-1, CD1d, CD16, 
CD32, CD80 (B7.1), CD115 (c-fms) and CD124 (IL-4Ra), but differ in the expression of 
F4/80, CD54, CD68 and CCR2 (that are low expressed by MO-MDSC and absent on PMN-
MDSC) and CXCR1 (that is only expressed by PMN-MDSC) (34, 39-40). In human these 
cells express CD11b, CD33, CD66b and CD124. In addition, PMN-MDSC expresses CD15 
and VEGF-receptor and MO-MDSC express CD14 and are able to express HLA-DR at low 
levels (35, 40).
 Additionally, a third population has been defined; however this group is rare compared to 
the PMN-MDSC and MO-MDSC populations. Since most studies focus on the more abundant 
groups of MDSC, not much is known about this subpopulation. This population consists of 
Gr-1low expressing myeloid cells, but lack markers of mature myeloid cell types. Based 
on sideward scatter (SSC) of CD11b+Gr-1low cells, this population can be subdivided into 
two populations; SSClow and SSChigh cells. SSClow cells harbour immune suppressive 
capacities, whereas the SSChigh cells are not immune suppressive (36, 39). More research 
is required to determine how these cells contribute to tumour progression.
1.5.2. Recruitment of MDSC
MDSC are found in blood, the lymphoid organs and in the tumour of tumour-bearing hosts. 
Recruitment of MDSC is largely depending on tumour-derived factors and factors expressed 
by stromal cells / inflammatory cells associated with tumour cells. Several chemokines are 
reported to play a dominant role in the recruitment of MDSC from the bone marrow to 
the lymphoid organs and the tumour site. Under pathological conditions stimulation of 
myelopoiesis and inhibition of differentiation of myeloid cells leads to the accumulation 
of these cells. One of the most important factors during carcinogenesis enhancing the 
myelopoiesis of MDSC is VEGF. VEGF is best known as a pro-angiogenic growth factor, 
stimulating tumour vascularisation, however, it is now well established that VEGF is also 
required for MDSC recruitment (35). Other tumour-derived factors, which are involved 
in MDSC recruitment, are granulocyte /macrophage colony stimulating factors (GM-CSF, 
G-CSF and M-CSF). Stromal cells associated with tumours can produce factors (like IL-
1b, IL-4, IL-6, IL-10, IL-13, IFN-g and prostaglandins) that stimulate the recruitment of 
MDSC (35, 41). In addition, MDSC themselves can also contribute to accumulation and 
activation via the production of pro-inflammatory mediators (like IL-6 and S100A8/A9) 
functioning as an autocrine feedback loop (42). The signalling pathways in MDSC that are 
triggered by most of these factors converge on Janus kinase (JAK) protein family members 
and signal transducer and activator of transcription (STAT). STAT3 is most likely the main 
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transcription factor that regulates the expansion of MDSC (43-45). 
1.5.3. Immune suppression by MDSC
Activation of MDSC not only requires tumour-derived factors, but also IFN-g produced 
by T cells and factors secreted by tumour stromal cells (like IL-1b, IL-4, IL-6, IL-10, IL-
13). Most cytokines trigger STAT family of transcription factors. In addition, the arginase 
metabolism in MDSC is depending on tumour-derived prostaglandin E2 (PGE2). Activation 
of cytokine receptors on MDSC leads to activation of STAT-signalling pathways, resulting 
in the production of immune suppressive substances (like TGF-b, ROS and NOS) (35, 
41). MDSC contribute to tumour-associated immune dysfunctions through a myriad of 
mechanisms, including production of nitric oxide, arginine depletion, and production of 
reactive oxygen species
MDSC are found at different locations in tumour-bearing hosts. These cells can accumulate 
in tumour tissue, blood, and in lymphoid organs. MO-MDSC are mainly found at the 
tumour site and can inhibit the anti-tumour response in an antigen non-specific manner 
by the production of NO. High expression of the enzyme iNOS, leads to the generation of 
NO. NO can suppress T cell function though various mechanisms involving the inhibition 
of the cell signalling pathways and inducing DNA-damage to T cells. DNA-damage leads 
to the induction of T cell apoptosis. High arginase metabolism in MO-MDSC prevents the 
upregulation of cell cycle regulators in T cells, leading to the inhibition of the proliferation 
(35, 46). The suppressive activity of MDSC has been associated with the metabolism of 
L-arginine. L-arginine serves as a substrate for two enzymes: iNOS, which generates NO, 
and arginase, which converts L-arginine into urea and L-ornithine. MDSC express high levels 
of both arginase and iNOS, and a direct role for both of these enzymes in the inhibition 
of T-cell function is well established (46-48). Recent data suggest that there is a close 
correlation between the availability of arginine and the regulation of T-cell proliferation (49-
50). The increased activity of arginase in MDSC leads to enhanced L-arginine catabolism, 
which depletes this non-essential amino acid from the microenvironment. The shortage 
of L-arginine inhibits T-cell proliferation through several different mechanisms, like for 
example preventing their upregulation of the expression of the cell cycle regulators (46).
PMN-MDSC are found in blood, lymphoid organs and at the tumour site where they can 
suppress T cell activation in an antigen specific manner by the production of reactive 
oxygen species (ROS). MDSC capable of producing ROS are also capable of producing 
peroxynitrite, which is responsible for most of the adverse effects on T cells, linked to ROS. 
Peroxynitrite induces the nitration of several amino acids. Changes caused by nitration of 
the T cell receptor makes T cells incapable of interacting with the MHC complex on antigen 
presenting cells, which is necessary to obtain T cell specific stimulation (51-53). Besides, 
increased arginase 1 metabolism in MDSC enhances L-arginase catabolism, resulting in 
the downregulation of the CD3z-chain expression. This leads to alteration of the T cell 
receptor, contributing to the inducing of T cell tolerance by PMN-MDSC (35, 51).
Besides the induction of T cell anergy and T cell apoptosis, MDSC can also inhibit T cell 
proliferation by producing TGF-b. In addition, MDSC can also inhibit other anti-tumour 
cells, like NK- and NKT- cells, via TGF-b depending mechanisms. MDSC can bind to the 
TGF-b receptor on target cells via membrane bound TGF-b, leading to activation of intra 
cellular pathways resulting in downregulation of NK specific receptors (54).
19Tumour-induced immune suppression and immunotherapy
Ch
ap
te
r 
1
 
Figure 3 MDSC are accumulation in the lymphoid organs as well as at the tumour site by tumour/stromal 
cell derived factors, like VEGF. This leads to an influx of MDSC in the lymphoid organs and in tumour tissue. 
In the lymphoid organs and at the tumour site the anti-tumour response is blocked by products secreted 
by MDSC. ROS production leads to downregulation of the z-chain on T cells. MDSC can inhibit NK and NK-T 
cells via membrane bound TGF-b, which leads to the downregulation of NK-specific receptors. NO production 
by MDSC can induce T cell apoptosis and inhibit T cell proliferation. MDSC require tumour-derived PGE2 and 
T-cell-derived IFN-g for their function. In addition, the S100 family of inflammatory mediators production by 
MDSC can function as an autocrine stimulating factor.
1.5.4. Interaction with Tregs
In addition to their direct immune suppressive capacities, MDSC can also indirectly enhance 
immune suppression via the induction of regulatory T cells. Several studies reported that 
there is a distinct relation between regulatory T cells and MDSC. Although the exact 
mechanisms are not completely understood and may differ between tumour types, is has 
been shown that MDSC can induce Treg-expansion. Moreover, MDSC can also promote 
suppression of tumour-specific cytotoxic T cells by Tregs by processing and presenting TAA 
to T cells. TAA presentation in combination with IL-10 and TGF-b stimulation leads to the 
transcription of FoxP3+ by T cells (59-62). 
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1.5.5. MDSC as precursor cells
Although MDSC are mainly known for their immune suppressive capacities, they also 
contribute to tumour progression via several other mechanisms. Since the heterogeneous 
population of MDSC consists of immature myeloid cells, part of these cells are pluripotent 
and capable of differentiating into mature cell types. In the presence of appropriate 
growth factors and cytokines, MDSC can differentiate to dendritic cells, macrophages or 
endothelial cells (35, 52, 59).
Recent investigations led to the consideration that MO-MDSC can differentiate to TAMs. 
Since tumour-associated macrophages are the major inflammatory cell type within 
the tumour microenvironment, it has been proposed that MO-MDSC can function as a 
source for TAMs (60-61). As MO-MDSC migrate to the tumour site they downregulate 
ROS production and upregulate their arginase 1 and iNOS expression. Part of this cell 
population is rapidly differentiated to macrophages. The increased expression of arginase 
1 and NO is maintained by TAMs that are already present in the microenvironment (59).
It has been suggested that distinct MDSC populations can function as endothelial progenitor 
cells (EPC) (62). These cells are characterized by the expression of the endothelial marker 
CD31 and Tie-2 and can be incorporated into the vascular endothelium. However, it is still 
unclear under which conditions these MDSC can differentiate to endothelial cells but it 
has been established that MDSC can contribute to lympho- and angiogenesis (62). PMN-
MDSC are capable of producing matrix metallo-proteinase-9 (MMP-9), an enzyme involved 
in matrix degradation. MMP-9 contributes to the regulation of tumour-vascularisation. 
It has been suggested that the cleavage of the extracellular matrix contributes to the 
bioavailability of VEGF within the tumour microenvironment (63). In addition, MDSC 
themselves can also produce pro-angiogenic factors (like VEGF and prokineticin-2) 
enhancing blood vessel formation.
 
1.5.6. Conclusion
Recent studies investigating the role of these cells in cancer have led to the establishment of 
this cell type as an important immune regulatory cell (35). However, several aspects of this 
heterogenic cell population require further investigation. For example, the roles of specific 
MDSC subsets in mediating T-cell suppression, and the molecular mechanisms responsible 
for inhibition of myeloid-cell differentiation, need to be elucidated. In addition, as many 
investigations on these cells are performed in murine models, better characterization of 
human MDSC and whether targeting these cells in patients will be of clinical significance 
should be the main focus of future research. Nevertheless, it is indisputable that these cells 
contribute to tumour immune escape by inhibiting anti-tumour responses and therefore 
these cells are an interesting target to improve novel therapeutic approaches. 
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1.6. Tumour-associated macrophages (TAMs)
1.6.1. Identification of TAMs
Among the cells present in the tumour microenvironment, TAMs are a major component 
of the host leucocytic infiltrate (64). Classically activated (M1) macrophages, following 
exposure to IFN-g, have tumouricidal activity and elicit tissue destructive reactions. In 
response to IL-4 or IL-13, macrophages undergo alternative (M2) activation. In general, 
M2 macrophages are oriented to tissue repair and remodelling, immunoregulation, 
and tumour promotion. TAMs generally have the phenotype and functions similar to 
M2 macrophages and display a defective NF-kB activation in response to different pro-
inflammatory signals (65-66). They can be characterized on surface expression of general 
macrophages markers (Murine: F4/80, MHCII, CD11b and CD11c; Human: HLA-DR, 
CD11b, CD11c) and the expression of mannose-receptor (CD206) and scavenger receptor 
(CD163). Adjacent to this, macrophage phenotype can be identified based on expression 
of cytokines, chemokines and growth factors (For example, M1 macrophages are capable 
of producing IL-12 and IL-6, whereas M2 macrophages can produce IL-10, CCL17 and 
CCL22) (64, 67).
1.6.2. Recruitment of TAMs
TAM recruitment in tumours is mediated by cytokines belonging to different classes 
including colony stimulating factor-1, VEGF and chemokines (like CCL2) (68). As described 
previously (1.5.5.), it has been shown that MO-MDSC are capable of differentiating 
towards TAMs. Therefore, similar recruitment factors are described that contribute to the 
infiltration of TAMs and MDSC into tumour tissue (69-70). 
 In addition, dynamic changes of the tumour microenvironment occur during the transition 
from early neoplastic events toward advanced tumour stages. These events drive the 
switch from a M1 macrophage toward the M2 type by profound changes occurring in 
the tumour microphysiology (e.g. hypoxia, glucose levels, pH). The presence of hypoxic 
areas is found in most forms of solid tumour. TAMs accumulate in areas where hypoxia 
occurs. Hypoxia-inducible factor 1 (HIF-1) has been shown to control the cellular response 
to hypoxia and is essential for myeloid infiltration. As M1 macrophages are attracted 
to the tumour site during the elimination phase to eradicate tumour cells, changes in 
tumour microphysiology can occur during the equilibrium phase which leads to a shift in 
phenotype toward M2. This shift drives macrophages to production of factors (like MMP-9, 
VEGF and TGF-b) facilitating tumour cell proliferation, tumour cell migration and invasion, 
angiogenesis and tumour immune escape (68).
1.6.3. Immune suppression by TAMs
TAMs are able to suppress the adoptive immune response through various mechanisms. 
TAMs acquire a M2 phenotype, which is characterized by the production of immune 
suppressive cytokines, like IL-10, IL-6, IL-1b, TGF-b, CCL17, CCL18 and CCL22. The inability 
to produce pro-inflammatory cytokines has been assigned to defective NFkB activation in 
TAMs. IL-10 in combination with IL-6 can lead to upregulation of molecules in TAMs, which 
are implicated in suppression of tumour-specific T cell immunity (71). In addition, T cell 
activation is blocked by the enzyme indoleamine dioxygenase (IDO). IDO catalyzes the 
catabolism of tryptophan, an essential amino acid acquired for T cell activation (72).
 In addition, TAMs also contribute to immune suppression via indirect ways. Secretion 
of CCL18 leads to recruitment of naïve T cells. Attraction of naïve T cells into the tumour 
microenvironment is likely to induce T cell anergy (73-74). Besides CCL18, CCL17 and 
CCL22 are abundantly expressed. These cytokines interact with CCR4 receptor, expressed 
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by Tregs and induces T-helper 2 polarization (75). Via expression of VEGF, TAMs can block 
antigen uptake by antigen presenting cells and attract MDSC, which can function as TAM 
precursors but are also actively suppressing T cell function (as described previously 1.5.3 
and 1.5.5). MDSC are depending on PGE2 for their function. PGE2 is secreted by many 
types of cancer; however TAMs are also capable of producing PGE2 and therefore assist 
MDSC function (39).
1.6.4. Angiogenesis and tumour invasion
In literature TAMs are particularly reported for their contribution to angiogenesis and 
promoting tumour invasiveness. In tumour stroma, macrophages can produce enzymes 
leading to degradation of the extracellular matrix. MMPs are overexpressed in various types 
of cancer, especially MMP-2 and MMP-9. MMP can be produced by PMN-MDSC, tumour 
cells and TAMs. Overexpression of MMPs leads to increased cleavage of the extracellular 
matrix. During this process several cytokines, chemokines and growth factors are released 
from the matrix that promotes and facilitates endothelial cell survival and migration and 
thereby enhances angiogenesis (76). Besides indirect mechanisms, angiogenesis is also 
directly stimulated by TAMs. TAMs can produce proangiogenic factors like VEGF and platelet
Figure 4 TAMs are recruited by HIF-1a-induced and tumour/stromal cell secreted factors, like CCL2 and 
VEGF. These factors stimulate the myeloid-haematopoiesis, leading to the accumulation of myeloid precursor 
cells. These cells are recruited to the tumour site where they rapidly differentiate into macrophages. TAMs 
are distinctly polarized M2 macrophages, capable of producing immune suppressive cytokines (e.g. TGF-b). 
In addition they can recruit naïve T cells, which can lead to the induction of T-cell tolerance.  
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 derived growth factors (PDGF) (74, 77). The release of these factors leads to the formation 
of (lymph)angiogenic structures and subsequent dissemination of metastasis (78).
  
1.6.5. Conclusion
TAMs are key orchestrators of the cancer-related inflammation present in the tumour 
microenvironment. TAMs produce a host of growth factors for endothelial cells, as well as 
inflammatory cytokines and chemokines that contribute to tumour survival, proliferation and 
invasion. In addition, immunosuppressive mediators released by TAMs affect anti-tumour 
responses and facilitate tumour immune escape. Therapeutic targeting of macrophages 
represents a valuable strategy to complement established anticancer treatments.
1.7. Regulatory T cells (Tregs)
1.7.1. Identification of Tregs
Regulatory T cells (Tregs) entail a suppressive population of CD4+ T cells with a central 
role in the prevention of autoimmunity and the promotion of tolerance via their suppressive 
function on a broad repertoire of cellular targets (83-85). 
Characteristic of Tregs is the expression of CD25 (IL-2 receptor-a chain), forkhead/winged-
helix transcription factor box P3 (Foxp3), glucocorticoid-induced TNF-receptor-related-
protein (GITR), lymphocyte activation gene-3 (LAG-3), and cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4), however all these markers are not truly Treg-specific (86). 
Tregs can be divided into natural Tregs and adaptive Tregs. Natural Tregs are important in 
the suppression of autoreactive T cells that slip through selection processes and therefore 
natural Tregs maintain peripheral tolerance against self-antigens preventing autoimmunity. 
In humans, these cells represent 2-5% of total circulating CD4+ T cells in peripheral 
blood (87). Adaptive Tregs arise from naïve T cells and are triggered by suboptimal 
antigen stimulation and stimulation with TGF-b. Adaptive Tregs can be subdivided into 
IL-10 secreting Tregs type I (Tr1) and TGF-b producing Tregs (Th3 Tregs). These cells 
are characterized by the secretion of immune suppressive cytokines directly inhibiting 
T cells and converting DCs into suppressive APCs (88-90). Elevated levels of Tregs have 
been identified in blood of cancer patients compared with normal individuals and their 
presence predicts for poor survival (91). Tregs were first recognized to infiltrate human 
cancers and the prevalence of Tregs in tumour-infiltrating lymphocytes is much higher 
than their proportion in peripheral blood, constituting 20% or more of tumour-infiltrating 
lymphocytes (92-93).
1.7.2. Recruitment of Tregs
Natural Tregs are derived in the thymus and migrate into the periphery. Although it is 
generally accepted that the thymic function is largely reduced after adolescence, Tregs 
persist throughout human lifespan. It has been proposed that Tregs need to be activated 
and/or expended from periphery and bone marrow if needed. Since 25% of CD4+ T cells 
in the bone marrow function as Tregs, it has been suggested that the bone marrow plays 
an active role in humoral and cellular immune regulation. However, it is poorly understood 
which factors are involved in trafficking and regulation of Tregs (94).
It has been shown that Tregs play an important role in tumour immunity. Induction of 
suppressive activity of both, natural and adaptive Tregs, require T cell receptor triggering 
by antigen or stimulation with TGF-b (95-96). Weak stimulation or the absence of co-
stimulatory molecules leads to the induction of long-lasting suppressive activity. Via this 
mechanism, Tregs can also be directed against TAA and contribute to T cell anergy against 
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tumours. TAA-specific Tregs accumulate in the peripheral lymphoid organs and at the 
tumour side. However TAA-specific Tregs are also found in the bone marrow, suggesting 
that after activation Tregs can migrate back to the bone marrow and inducing T cell 
tolerance before these cells enter the circulation (94). Although exact mechanisms are 
not fully explored, it has been shown that CCR4+ (receptor for CCL22) Tregs migrate 
toward tumour microenvironments expressing CCL22 (97). Also CD62L and CCR7 have 
been described as important homing markers on Tregs (98). CD62L is critical for the 
migration of Tregs to draining lymph nodes. CCR7 is expressed by a majority of Tregs and 
is essential in homing to lymphoid organs and microenvironments expressing CCL19 (the 
ligand for CCR7) (97, 99). 
 
Figure 5 Tregs are attracted to the tumour site and the lymphoid organs by tumour-derived factors, like 
CCL22, CCL19 and CD62L. Here they can inhibit the anti-tumour response using a variety of mechanisms. 
They can inhibit effector cells by secretion of immune suppressive cytokines (e.g. IL-10, IL-35 and TGF-b). 
Besides, Tregs can kill APCs and effector cells by producing granzyme B and perforin. Via upregulation of 
cyclic AMP Tregs can inhibit proliferation of effector cells. 
1.7.3. Immune suppression by Tregs
Tregs inhibit CD4+ and CD8+ effector cells, dendritic cells and natural killer cells and 
secrete nonspecific, immunosuppressive molecules such as IL-35, IL-10 and TGF-β to 
blunt the immune response (100). However, recent studies showed that these cytokines 
are not the main suppressive factor, facilitating Treg-induced immune suppression (101).
In contrast, it’s becoming more distinct that direct cell-cell interaction between Tregs 
and target cells play a dominant role in tolerance induction by Tregs (102-105). Like 
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MDSC, Tregs can inhibit NK and NK T cells via membrane bound TGF-b . The binding of 
membrane-bound TGF-b on Tregs to TGF-b -receptor on target cells leads to the activation 
of intracellular pathways which eventually leads to the downregulation of the NKG2D-
receptor on NK and NK T cells (106). Other studies showed that cell-cell binding interacts 
with mechanisms leading to apoptosis (by activation of programmed cell death-ligands 
and the release of perforin and granzyme B) and reduced proliferation (by upregulation of 
intracellular cyclic AMP) (101). 
Besides the effects on target cells, Tregs disturb the induction of the adaptive immune 
response by preventing proper antigen presentation. Tregs forming aggregates around 
DCs prevent contact between DCs and T cells [94]. In addition, Treg-aggregation leads 
to decreased upregulation of CD80 and CD86 on immature DCs and downregulate the 
expression of CD80 and CD86 on mature DCs. These phenomena are antigen specific and 
dependent on lymphocyte function-associated antigen 1 (LFA-1) and CTL-associated protein 
4 (CTLA-4) (107-108). Though, the exact role of CTLA-4 in Treg-mediated suppression 
is still under extensive investigation. Additionally, activated Tregs, which express high-
affinity IL-2R, may absorb IL-2 from the microenvironment (109). More recently, it has 
been reported that Tregs can prevent the induction of an anti-tumour response by killing 
DCs in tumour-draining lymph nodes via a perforin-dependent manner (110).
 
1.7.4. Conclusion
Increased Treg numbers have been reported in the blood, lymphoid organs and tumour 
tissue of patients with distinct types of cancer. Elevated levels of Tregs have also been 
identified in blood of cancer patients and predicts for poor survival (91). In addition, 
Tregs in tumour-infiltrating lymphocytes is much higher than their proportion in peripheral 
blood, constituting 20% or more of tumour-infiltrating lymphocytes (92-93). Since these 
cells can inhibit the anti-tumour response in various ways, it leaves no doubt that Tregs 
play a critical role in tumour immune surveillance. Targeting these cells may therefore 
enhance the efficacy of novel therapeutic approaches.
   
1.8. Re-programming of the immune system
 
For many years, all efforts to treat cancer have concentrated on the destruction/inhibition 
of tumour cells. New insights have led to the establishment that immunosuppressive cell 
types in tumour environments play an important role in cancer progression. Therefore, 
it has been proposed that targeting MDSC, TAMs and/or Tregs is promising in refining 
innovative therapeutic strategies. Strategies to modulate the host microenvironment 
offer a complementary perspective. However, targeting of immune suppressive cells may 
lead to prolongation of survival by slowing down carcinogenesis; however in combination 
with activation of the immune system these strategies can unfold therapeutic potential. 
Therefore, the interest in the development of cancer vaccines has increased tremendously 
over the last few decades.
1.9. Immunotherapy 
Cancer immunotherapy attempts to make use of the ability of the immune system to 
generate an antigen specific response against tumour cells. Numerous approaches for 
immunotherapy have been developed. They can be divided into two strategies: passive 
and active therapy.
 Passive therapies rely on the administration of ex vivo expanded/produced 
immunologic effectors that are capable of directly targeting tumour cells. 
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Monoclonal antibody therapy: Humanized monoclonal antibodies are effective in several 1. 
human malignancies and during the last decade. Monoclonal antibodies can target cells 
in various ways. They can target cells directly (like for example Rituximab (anti-CD20) 
in the treatment of non-Hodgkin lymphomas (107) and Trastuzumab (anti-HER-2/Neu) 
in breast cancer) or by inducing tumour cell apoptosis. Other monoclonal antibodies 
can also target angiogenenic factors like VEGF (VEGF-inhibitor Bevacizumab) or be 
used as immunomodulators to inhibit immune suppressive molecules/cells or activate 
immune stimulatory molecules. Efficacy of this approach can be enhanced by linking 
these antibodies to a toxin (e.g. radionucleotides and anticancer drugs). 
Cell transfer of effector cells: Adaptive transfer of antigen specific effector cells (like 2. 
T cells and NK cells) can be expanded and/or activated ex vivo and subsequently 
administered back into the patient to attack the tumour. This approach showed the 
potential to reconstitute host immunity against pathogens, like Epstein-Barr virus 
(EBV) in immune suppressed patients, but more importantly also provides evidence 
that adaptive T cell transfers can prevent the induction of EBV-associated lymphomas 
(108). This led to the concept that antigen specific T cell transfer can be used as an 
anti-tumour therapy to eradicate established tumours. The effectiveness of adaptive 
T cell transfer to eradicate malignancies is challenging (109). 
Active immunotherapeutic approaches aim at inducing/boosting immune effector cells in 
vivo against tumour cells, through the administration of immune mediators capable of 
activating the immune system.
Cytokines: Several cytokines are capable of activating and recruiting specific immune 1. 
cells that can enhance anti-tumour immunity (e.g. IL-2, IL-12, IL-15, TNF-a, GM-CSF). 
These cytokines can be used as an approach as single treatment or in combination 
with other immunotherapy strategies (110)
Peptides & proteins: Defined TAA epitopes have been used to vaccinate cancer patients; 2. 
however this approach is limited by the relatively low number of identified epitopes 
and by the requirement of MHC typing. Nevertheless, some authors have reported the 
applicability of this approach. The need of peptide identification can be circumvented 
by using the whole TAA protein for immunization. These proteins can be taken up by 
APC and endogenously processed into epitopes for presentation to T cells. Adjuvants 
need to be added to induce APC activation and avoid tolerance induction (111-113).   
DNA: In this approach DNA sequences coding for specific TAA are directly injected into 3. 
the skin. DNA then needs to be taken up, transcribed into mRNA, translated into a 
protein and processed into peptides by APC. An important restriction is the relatively 
inefficient delivery into APC (111-113).  
Recombination viral vectors: Viruses engineered to express TAA can be injected 4. 
directly into the patient. The virus then transduces the host cell, leading to cell death 
and presentation of antigenic isotopes to the immune system. A wide variety of viral 
vectors are available. However there are concerns regarding the immuno-dominance 
of viral antigens over TAA, resulting in a strong antivirus response leading to virus 
eradication and attenuation of the anti-tumour immune response (111-112). 
Whole tumour cells: The ideal source of TAA is the tumour itself, since it expresses all 5. 
the TAA that need to be targeted. Tumour cell-lines are often used as source for this 
approach. Tumour cell-lines can be genetically modified to co-express cytokines or 
co-stimulatory molecules to enhance their immunologic capacity. However, in general, 
tumour cells display a rather weak antigen presentation capacity and because of the 
need for ex vivo tumour cell culture, this approach is rather expensive, time consuming 
and labour intensive (111-112).  
Dendritic cells: DCs have emerged as the most powerful initiators of immune 6. 
responses. In the natural activation of the adaptive immune system against tumour 
cells, DCs play a crucial role since they are capable to engulf tumour antigens and 
activate lymphocytes in an antigen specific manner. Therefore, the application of 
dendritic cells to therapeutic cancer vaccines has been prompted (114-115). DCs 
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can be generated in large amounts ex-vivo, and can be pulsed with tumour antigens 
in optimal conditions. Subsequently, the injection of matured tumour antigen-pulsed 
DCs leads to the induction of an anti-tumour response in murine models as well as in 
patients (116-119). Moreover, DC activation also induces the formation of antibodies 
against tumour components (117). Therefore, DC-immunotherapy can potentially 
induce long lasting immune protection.
Over the last decades numerous groups have investigated the safety and applicability 
of DC-based vaccines in the treatment of cancer in preclinal / clinical studies. DC-based 
vaccines are studied both in solid tumours and non-solid tumours. Most of the clinical trails 
have been performed in patients with advanced stages of disease. In the next chapter we 
introduce DC-based immunotherapy for the adjuvant treatment of mesothelioma.
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2.1. Malignant mesothelioma
Malignant mesothelioma (MM) is caused by a neoplastic transformation of mesothelial cells 
and occurs predominantly in the pleura and less frequently in the peritoneum, pericard or 
tunica vaginalis testis. Exposure to airborne asbestos fibers is the major causative agent. 
For the Netherlands, the peak of the epidemic is predicted around the year 2017. The most 
plausible scenario predicts an increase in pleural mesothelioma mortality up to 950 cases 
per year in men, with a total death toll close to 18.000 cases during 2000-2028. Currently, 
nearly 700 new cases are diagnosed each year with MM in the Netherlands. Rotterdam has 
the highest risk of MM at the national level and is responsible for 1% of overall mortality 
in men in this area. 
 With median survival durations of 9-12 months from onset of clinical symptoms, the 
prognosis is poor (1). Because of the limited success of conventional treatments, novel 
therapeutic regimens are urgently needed. Currently the combination of pemetrexed 
(ALIMTA, registered trademark of Eli Lilly and Company) and cisplatin is considered standard 
of care for patients with mesothelioma, as an increase in median survival of 3 months was 
noticed (2-5). This combination chemotherapy can reduce tumour burden, however this 
therapy is used as palliative treatment. A systemic review of the literature provides very 
limited evidence for the role of surgical cytoreduction in treating mesothelioma (6). It is 
extremely difficult, painful and not without serious complications (7). Therefore, there is a 
great need for new therapeutic approaches in these patients. One of the most challenging 
approaches is DC-based immunotherapy. 
2.2. Dendritic cell-based immunotherapy in malignant pleural mesothelioma
Pulsing of DCs can be done in various ways in-vivo and ex-vivo. In-vivo activation of 
DCs has been attempted by subcutaneous or intratumoural injection of GM-CSF with 
and without tumour lysate. However, since DC function is suppressed in-vivo by immune 
suppressive cells (MDSC and Tregs) and tumour derived soluble factors (e.g. VEGF) this 
strategy leads to difficulties. Therefore, expending the number of DCs ex-vivo, in the 
absence of immune suppressive components holds more potential. When specific tumour 
antigens are identified, single peptides can be used to load DCs (8). However, it has 
become increasingly clear that this “single target” approach is problematic. Since antigen 
expression by tumour cells is often very heterogeneous and not all tumour cells express 
similar antigens. Therefore, the use of single peptides results in an immune response 
limited to the epitopes used for immunization that might be insufficient to rapidly 
eliminate all tumours. As described previously, tumour cells can lose TAA expression to 
elicit an immune response. If these antigens are not required for growth of the tumour 
or maintenance of the transformed phenotype, the antigen-negative tumour cells have a 
growth advantage in the host. Eventually these will lead to outgrowth of those cells that 
do not express these TAA and thereby these tumour cells escape detection by T cells that 
are triggered to target that single TAA. Besides this, the efficacy of vaccination against a 
single or a few TAA is limited by peptide restriction to a given HLA type and the induction 
of CTL without CD4+ T helper cell activation. 
 Therefore, polyvalent therapeutic strategies, aimed at targeting many antigens at once, 
may overcome these problems. One such strategy is to load DC with tumour cell lysates, 
either from autologous or allogeneic background, without further defining the antigens. 
Lysate can be generated after collection of tumour material. Tumour cells can be UVB 
irradiated leading to apoptotic tumour lysate or subjected to freeze-thawing cycles giving 
rise to necrotic lysate. There is considerable controversy as to whether necrotic or apoptotic 
lysate is the superior source of tumour antigens to pulse DC for immunotherapeutic 
applications (9). Ex-vivo generated DCs can encounter these fragments and take up 
different antigens, providing them with a large scale of tumour-associated and tumour-
specific antigens. Therefore, tumour lysates might be advantageous in providing the full 
antigenic repertoire of the tumour and, particularly, unique tumour antigens, which will 
theoretically decrease the ability of tumours to evade the immune response by down 
regulation of a single antigen (10). It greatly diminishes the chance of tumour escape 
compared to using single epitope vaccines. Besides the role as antigen source, tumour 
lysate also serves a role in protein supplementation in DC culture (11). Furthermore, the 
use of tumour cell lysate theoretically eliminates the need to define, test and select for 
immunodominant epitopes. An example of a cancer which needs to rely on lysate pulsed 
DC-immunotherapy is malignant mesothelioma. 
 Many antigens that were originally identified as tumour specific are now known to be 
expressed in many other tissues. Mesothelioma-associated tumour antigens are limited to 
date and no mesothelioma specific tumour antigens are known. Mesothelin, calretinin, SV-
40, Wilms tumour 1 (WT-1), and telomerase have been described as TAA but these proteins 
are not expressed on the membranes of all MM tumours. Although research is performed 
to identify “better” TAA for MM, much work remains to be done. This may be useful in 
the early detection of mesothelioma for diagnostic purposes. However, immunotherapy 
based on a polyvalent therapeutic strategy is directly accessible for all types of cancer 
and diminishes the chances of rapid immune escape by lose of single TAA on tumour 
cells. In 2005 Hegmans et al. showed that is was feasible to use lysate pulsed dendritic 
cells to induce anti-tumour responses against MM in a murine model (12). To investigate 
if this strategy was also applicable in MM patients, a clinical trail, using dendritic cells 
loaded with autologous tumour-lysate, was adapted in the Erasmus MC (CHAPTER 3). 
Although we were able to show that an immune response could be generated and an 
anti-tumour response could be induced in part of the patients, refining this approach was 
recommended. One of the main reasons for reduced efficacy of immunotherapy in cancer 
patients is the presence of tumour-induced immune suppression (CHAPTER 1).
The aim of the work addressed in this thesis was to refine immunotherapy 
by targeting immune suppressive cells with the intention to enhance the 
affectivity of the induced anti-tumour response.       
To investigate approaches to refine immunotherapy, we aimed to target immune 
suppressive cells. In the immunesuppressive environment MDSC, TAMs and Treg play 
a dominant role (CHAPTER 1). We aimed to determine the capacity of agents to target 
these cells in a murine model for mesothelioma. Simplifying the nature of cancer by 
analyzing only the cancerous cells either in tissues or after propagating in culture will lose 
important information on the biological reality of tumours in vivo. In our need to make 
investigations translational to the clinic, we analyzed three clinical applicable agents with 
are on the market, but used for the treatment of other diseases then cancer. 
 We evaluate a strategy to overcome immune suppression by MDSC. MDSC are a relatively 
new cell type and were first described by Bronte and Gabrilovich in 2000/2001 (13-14). 
These cells can affect antitumour-immunity via an antigen-specific and non-specific 
manner. However, both suppressive mechanisms are largely depending on tumour-derived 
PGE2. COX-2 is essential in the formation of PGE2. Therefore we tested a selective COX-2 
inhibitor (Celecoxib) to reduce PGE2 production by tumour cells. This was tested in an 
animal model for mesothelioma. Results of this refinement are reported in CHAPTER 4. 
 The role of TAMs during tumour pathogenesis and tumour progression has been studied 
extensively. However, targeting TAMs by using clinical applicable agents seems difficult. 
One of the agents which seem to hold promise in targeting TAMs are bisphosphonates. 
Recently, is has been discussed that Zoledronic acid (ZA) may have anti-tumour potentials, 
since Gnant et al. showed that ZA prolongs disease-free survival in patients with breast 
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cancer (15). The mechanism via which ZA prevents disease progression is still unclear. 
It has been suggested that ZA modulates the immune response and may influence 
macrophage phenotype (16-18). In CHAPTER 5 we determined the effect of ZA on TAMs 
in a murine model for mesothelioma.
 In CHAPTER 6 we focussed on the role of regulatory T cells in mesothelioma. Hegmans 
et al. showed that Tregs can be reduced with a depleting antibody PC61, however the 
specificity of this antibody is not sufficient in the combination with immunotherapy since 
PC61 also depletes activated T and B cells (19). Recent clinical studies have shown 
that low-dose cyclophosphamide (CTX) induces beneficial immunomodulatory effects 
in the context of active or adoptive immunotherapy (20-30). CTX is widely used to 
treat various types of malignancies and some autoimmune disorders. It displays either 
immunosuppressive or immunopotentiating effects, depending on the dosage and the 
timing of drug administration (31). CTX was given to mice in a metronomic low-dose 
treatment protocol in a mesothelioma mouse model. The results of this treatment strategy 
have eventually led to the initiation of a new clinical trail. CHAPTER 7 reports the study 
design of the newly initiated trial. 
In CHAPTER 8 we postulate the hypothesis that dendritic cell-based immunotherapy can 
be refined by simulteneously targeting tumour-induced immune suppression. Furthermore, 
the contribution of this thesis to the therapeutic application of immunotherapy and the 
treatment of cancer patients in general are discussed.
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SPECIFIC AIMS: In 2010, we published the first clinical 
study demonstrating that injection of tumor lysate-
pulsed autologous DCs injected in patients with MM 
after chemotherapy was safe and well-tolerated. 
There were no grade 3 or 4 toxicities associated with 
the vaccines or any evidence of autoimmunity. Local 
accumulations of infiltrating T cells were found at the 
site of vaccination. The vaccinations induced distinct 
immunological responses to KLH, both in vitro and in 
vivo. Importantly, after three vaccinations, cytotoxic 
activity against autologous tumor cells was detected in 
a subgroup of patients (CHAPTER 3).
It is known that the induced anti-tumor immunity in 
cancer patients is created in an unfavorable highly 
suppressive tumor environment, influencing the 
therapeutic efficacy of DC-based immunotherapy 
negatively. We believe that the full therapeutic 
potential of DC-based immunotherapy for mesothelioma 
patients can therefore be further exploited. Regulatory 
T cells (Tregs) play a pivotal role in the suppressive 
environment created by the tumor. We have shown in 
a mouse mesothelioma model that modulation of Tregs 
using metronomic cyclophosphamide (CTX) could 
enhance the anti-tumoral immune responses elicited 
by DC vaccines (CHAPTER 6). In our current study, ten 
patients with stable disease or partial response after 
chemotherapy are subjected to a combined treatment 
with DC-based immunotherapy and simultaneously oral 
CTX administration. 
STUDY ENDPOINTS: the primary endpoint of the 
study is: to determine the effect of metronomic 
cyclophosphamide during DC-based immunotherapy 
on the reduction of regulatory T cells in peripheral 
blood of MM patients (by laboratory measurements). 
Secondary endpoints: A) Determination of the effect 
of regulatory T cell depletion on specific anti-tumor 
activity (laboratory measurements), B) Determination 
of clinical responses (CT scans, time-to-progression, 
and survival) and to define the safety and toxicity of 
this combined treatment in MM patients.
CLINICAL RELEVANCE: The findings of this study are 
important to demonstrate if the immune system can 
be subverted from a suppressive environment to a 
stimulating situation in cancer patients. 
The study is approved by the Central Committee 
on Research involving Human Subjects (CCMO) as 
defined by the WMO (Medical Research Involving 
Human Subjects Act 1999) [MEC-2008-109/CCMO 
NL24050.000.08, EudraCT number 2008-000957-36
Keywords: DC-based immunotherapy, mesothelioma, cyclo-
phosphamide, regulatory T cells
PATIENT ELIGIBILITY
PATIENT INCLUSION
Patients with suspicion of pleural MM and who are considered 
to be fit enough to be treated with chemotherapy will be asked 
to participate in this study. Also treatment naive patients who 
have already been diagnosed with MM with a medical need
Supported by the Stichting Asbestkanker Rotterdam, Stichting Coolsingel, 
Nico Heijmer Foundation, Fonds Schiedam Vlaardingen, Fonds NutOhra, 
and the Mesothelioma Applied Research Foundation (MARF).
for a pleural puncture are asked to participate. When patients 
are diagnosed with MM of the epithelial subtype, they will be 
informed about standard treatment and this experimental 
study protocol. Ages eligible for study: 18 years - 85 years 
(both genders). 
Standard treatment at this moment includes 4 courses 
of chemotherapy with Alimta ([pemetrexed disodium, 
FDA approval February 5, 2004], Eli Lilly and company, 
Indianapolis, U.S.A.). Then, ten patients will be asked to 
participate in adjuvant treatment with low dose of CTX in 
combination with DC-based immunotherapy. Only patients 
will be included in this trial when a stable disease or partial 
response occurs after chemotherapy. Response assessment 
will be done according to modified RECIST criteria. 
In case of progressive disease after chemotherapy, both for 
ethical and study related reasons, patients will not be treated 
with DC-immunotherapy and will be treated according to 
patient and clinicians decision. Inclusion and exclusion criteria 
are summarized in table 1. In addition, table 2 overviews pre-
study screening that needs to be performed before inclusion.
STUDY DESIGN
The working plan is to inform patients with suspicion for MM 
to participate in our study protocol, only when they are fit 
enough to be treated with chemotherapy. Patients will be 
informed about the suspicion of MM and the need to perform 
further diagnostic analysis. The diagnostic process of MM 
includes the removal of pleural fluid by pleural puncture. 
Patients will be asked to agree that the excess of the pleural 
fluid, which is normally discarded, is sent to the laboratory 
for cell culture and preparing tumor lysate. When a patient 
is not diagnosed for MM, all patients’ corresponding material 
will be destroyed. In case the diagnosis is not obtained from 
the cytology of the effusion fluid (> 30% of the cases), a 
thoracoscopy is routinely performed in order to obtain an 
appropriate diagnosis (this is a standard procedure). With this 
technique, histological specimens from a visible tumor are 
collected for diagnosis. Patients will then be asked to agree 
on taking four additional tumor samples for the preparation 
of tumor lysate. 
Patients will receive chemotherapy (4 cycles of Alimta/
cisplatin). Then, ten patients who had stable disease or 
partial response after chemotherapy are asked to participate 
in adjuvant treatment with low dose of CTX in combination 
with DC-based immunotherapy. 
After a resting period of 8 weeks, leukapheresis is performed to 
obtain monocytes for the differentiation to DCs in a cleanroom 
facility. The procedure to obtain DCs in vitro and pulse them 
with tumor lysate is performed according to our previous DC-
immunotherapy protocol (CHAPTER 3). Three doses of pulsed 
autologous DCs are then re-injected every two weeks as 
shown in Figure 1. Quality control tests are performed before 
the cellular vaccine is released by an accredited Qualified 
Person (Pharmacist). 
Patients will be treated with metronomic CTX (Endoxan) for 
seven day in a row the week before the 1st vaccination [week 
22], in the weeks between the 2nd and 3rd [week 24 and 
26], and for one week after the 3rd DC vaccination [week 28] 
(Figure 1). The dose of CTX is 100 mg (two [2] tablets)/day. 
The patient will take the medication 2 hours after breakfast 
and after diner and will be asked to increase their fluid intake 
by extra drinking water or other non-caffeinated beverages 
Dendritic cell-based immunotherapy combined with regulatory T cell 
depletion for the adjuvant treatment of malignant mesothelioma. 
Study design of the newly initiated trial.
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throughout the day. 
Liver and kidney function is checked to prevent complications 
of medication and CT-contrast agents during therapy. 
Additionally, one week after cyclophosphamide treatment, 
urine of patients is routinely checked for signs of hematuria, 
to avoid complications caused by side effects of medication. 
During vaccination procedures patients are restricted to the 
department of Pulmonary Medicine at the Erasmus MC for 
a four hour period for observation. Blood pressure, body 
temperature and oxygen saturation are checked routinely 
until four hours after vaccination.
TREATMENT EVALUATION AND CLINICAL FOLLOW-UP
SAFETY AND TOXICITY
To define the safety and toxicity of the combination of 
metronomic CTX (orally) and tumor lysate-pulsed DCs 
injected intradermally and intravenously in patients with MM 
after chemotherapy. Serum and blood samples are regularly 
tested for liver and renal functioning and for the development 
of auto-immunity by analysis of ANA, ENA and rheumatoid 
factors.
IMMUNE RESPONSES
Serum and blood samples will be taken at numerous time 
points for leucocyte analysis (B cells, T cells [Tregs and 
CTLs]), IFN-gamma ELISPOT and other cytokines to reveal 
immune responses and tumor-specific responses. Humoral 
responses to the model antigen ‘keyhole limpet hemocyanin 
(KLH)’ are measured in the serum by ELISA. Tregs will be 
analyzed by polymerase chain reaction (PCR) for the presence 
of the transcription factor FoxP3, GITR and CTLA4 expression. 
Viable Tregs will be identified, isolated, and characterized from 
patient blood samples using CD4, CD25 and CD127 antibodies 
and sorted using a cytometry sorter FACSaria. Cells will be 
functionally analyzed in vitro in a suppression assay with 
responder lymphocytes at different ratios in the presence 
of a stimulus (Treg Suppression Inspector, Multinyi Biotec). 
In addition, anti-tumor activity is measured using 4 hour 
incubation of PBMC from specific time-points with radioactive 
(51Cr) labeled autologous tumor cells. Lysis of tumor cells in 
this period is determined by gamma-scintillation counting.
To determine if this immunization results in a detectable 
immune response, DTH tests will be performed twice (Skin 
DTH tests at week 17/18 and 29). Therefore, unpulsed DCs, 
DCs pulsed with tumor lysate, DCs pulsed with KLH and tumor 
lysate will intradermally be injected at the inner side of the 
forearm with approximately 1.000 DCs / site. Readings are 
carried out after 48 hours.
A positive reaction is characterized by an induration of at 
least 5 mm. Each positive reaction should be recorded as 
the sum of the perpendicular diameters divided by 2. Six 
millimeter punch biopsies might be taken from the positive 
reactions and tested for CD4, CD8, and NK cells using 
immunohistochemistry. All DTH results will be recorded in the 
patient’s chart. The reading will be assessed preferably by 
the same study coordinator. Digital color photographs of the 
TABLE 1 
 INCLUSION CRITERIA
Patients with clinically and histological or • 
cytological confirmed newly diagnosed MM, that 
can be measured by modified RECIST criteria by a 
radiologic imaging study.
Patients must be at least 18 years old and must be • 
able to give written informed consent.
Patients must be ambulatory (Karnofsky scale > • 
70, or WHO-ECOG performance status 0 or 1) 
and in stable medical condition. The expected 
survival must be at least 9 months at the time of 
diagnosis.
Patients must have normal organ function • 
and adequate bone marrow reserve: absolute 
neutrophil count > 1.5 x 109/l, platelet count > 
100 x 109/l, and Hb > 6.0 mmol/l.
Positive DTH skin test (induration > 5 mm after 48 • 
hrs) against at least one positive control antigen 
tetanus toxoid after finishing of chemotherapy.
Stable disease or any response after chemotherapy • 
as determined with modified RECIST criteria
Availability of sufficient tumor material of the • 
patient to load dendritic cells, determined at the 
department of pulmonary disease of the Erasmus 
MC.
Ability to return to the Erasmus MC for treatment • 
related procedures and adequate follow-up as 
required by this protocol.
Able to tolerate oral therapy with • 
cyclophosphamide.
No impairment of gastrointestinal (GI) function or • 
GI disease that may affect or alter absorption of 
cyclophosphamide (e.g. mal-absorption syndrome, 
history of total gastrectomy/significant small bowel 
resection).
No history of allergic reactions (> grade 3 or 4) • 
to compounds of similar chemical or biologic 
composition to CTX (i.e., alkylating agents). 
No known intolerance or hypersensitivity reaction • 
to CTX 
EXCLUSION CRITERIA
Conditions that make the patient unfit for • 
chemotherapy or progressive disease after 4 cycles 
of chemotherapy.
Pleurodesis at the affected side before the pleural • 
fluid is obtained.
Medical or psychological impediment to probable • 
compliance with the protocol.
Patients on steroid (or other immunosuppressive • 
agents) are excluded on the basis of potential 
immune suppression. Patients must have had 6 
weeks of discontinuation and must stop any such 
treatment during the time of the study.
No prior malignancy is allowed except for adequately • 
treated basal cell or squamous cell skin cancer, 
superficial or in-situ cancer of the bladder or other 
cancer for which the patient has been disease-free 
for five years.
Serious concomitant disease, no active infections. • 
Patients with a history of autoimmune disease or 
organ allografts, or with active acute or chronic 
infection, including HIV (as determined by ELISA and 
confirmed by Western Blot) and viral hepatitis (as 
determined by HBsAg and Hepatitis C serology).
Patients with serious intercurrent chronic or acute • 
illness such as pulmonary (asthma or COPD) or 
cardiac (NYHA class III or IV) or hepatic disease or 
other illness considered by the study coordinator 
to constitute an unwarranted high risk for 
investigational DC treatment.
Patients with a known allergy to shell fish (may • 
contain KLH).
Pregnant or lactating women.• 
Patients with inadequate peripheral vein access to • 
perform leukapheresis.
Concomitant participation in another clinical trial.• 
An organic brain syndrome or other significant • 
psychiatric abnormality which would comprise the 
ability to give informed consent, and preclude 
participation in the full protocol and follow-up.
Absence of assurance of compliance with the • 
protocol. Lack of availability for follow-up 
assessment.
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skin DTH response will be taken and all results are stored 
confidentially according to Personal Data Protection Act (WBP: 
Wet bescherming persoonsgegevens).
CLINICAL RESPONSES
CT-scans (at least at week 1, 14, 21, 31), re-staging tests, and 
time to progression will be performed at scheduled intervals 
throughout the study. To observe and document the clinical 
response in MM patients who receive the complete treatment, 
as measured by the evolution of evaluable and measurable 
disease lesions in response to the treatment. 
LIFELONG FOLLOW-UP OF PATIENTS
All patients will be seen at specified intervals during the study. 
After finishing the study protocol, patients are re-directed to 
the most appropriate outdoor hospital at regular intervals 
according to standard clinical practice. Study coordinator 
maintains lifelong contact with patient / general practitioner. 
PROJECT EVALUATION (SUCCESS OR FAILURE)
Historical controls and the earlier performed study (CHAPTER 
3) are used for the interpretation and evaluation of the results. 
Then, all patients had an induction of immune responses 
against KLH and an increase of the percentage of granzyme B 
CD8+ cells between pre-vaccination and post-vaccination. We 
anticipate this will be found in >90% (>9) of the participat-
ing patients in this study, indicating that the injected dendritic 
cells are capable of inducing stronger immune responses.
Important factors to continue or impediment the strategy of 
modulating the suppressive environment during DC-based 
immunotherapy are : 1). a decrease of 25% in the percentages 
of Tregs within the CD4+ T cell population in peripheral blood 
(was 9.8%) by CTX intake in at least 70% of patients (at 
week 30/31), 2). at least an increase of 10% in tumor specific 
lysis (was 4.9%) in more than 60% of the patients (week 
30/31). These results are combined with CT-scan findings
(was 30% partial response), safety and toxicity findings, and
Acknowledgment: We thank Eric Braakman and Anita Schelen 
from the Department of Hematology for clean room use. Meriam 
Grootes and others are thanked for apheresing the patients. Arnold 
Vulto and Anna de Goede are thanked for their expert-advices on 
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clinical findings (time to progression, median survival (was 19 
months)) for considering the effectiveness of the project 
CURRENT STATUS
6 of the 10 patients have been treated with adjuvant DC-
based immunotherapy in combination with metronomic CTX. 
Preliminary data showed that DC-based immunotherapy 
combined with CTX is as safe and feasible as single treatment 
with DC-based immunotherapy. As described in our previous 
trial, self-limiting fever-like symptoms were observed after 
second and third vaccination; thus far no side effects were 
reported during treatment with the combination of DC-based 
immunotherapy with metronomic CTX. To avoid confirmation 
bias on interpretation of data, no analysis on Treg number 
and function can be performed in this ongoing trail. These 
analyses will be performed after completion of the study. We 
anticipate completing this clinical trial by the end of 2011.
Figure 1. Synopsis of the study consisting of a 
combined treatment with chemotherapy followed 
by active immunotherapy using autologous 
tumour lysate-loaded dendritic cells (DCs) in 
combination with metronomic cyclophosphamide 
(CTX 100mg; administration: 50mg tables 2dd1). 
DTH = delayed type hypersensitivity.
TABLE 2
PRE-STUDY SCREENING
All eligibility criteria should be assessed together with 
relevant baseline parameters within 21 days prior to 
initiation of the DC-based immunotherapy (week 17/18).
The following tests must be performed:
Medical history and complete physical examination • 
(performance status, including inclusion/exclusion 
criteria, blood pressure, weight, and body 
temperature). 
Clinical laboratory tests will include at least: • 
complete blood count and differential count, 
creatine, urea and ionogram (including 
sodium, potassium, calcium), bilirubin, lactate 
dehydrogenase, creatine phosphokinase, 
transpeptidases and aminotransferases, serum 
proteins (total protein and albumin), ANA-titer.
Radiological studies documenting tumor location.• 
Viral serology: HTLV-I, -II and HIV antibodies, • 
HBV antigen, and HCV antibodies. 
Bacteria serology: Syphilis• 
DTH skin test with tetanus toxoid• 
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Chaptier 8 Summarizing discussion
The studies presented in this thesis describe strategies to improve dendritic cell-based 
immunotherapy. To refine this approach we focused on targeting immune suppressive 
cells that are abundantly present in tumour-bearing hosts. In CHAPTER 3, the outcome 
of our clinical phase I trial is presented. In this chapter we showed that the administration 
of dendritic cells loaded with autologous tumour lysate is save and feasible, but more 
importantly, we were able to detect a specific anti-tumour response in the blood of 
patients (4 out of 6). However, optimization of this strategy was recommended to expand 
therapeutic potential.
 The presence of immune suppressive cells has been proposed to be one of the main 
factors negatively effecting the induced immune response generated by immunotherapy. 
As described in chapter 1; MDSC, Tregs and TAMs are abundantly present in tumour 
environments. We aimed to determine the effectiveness of clinical agents in targeting 
of these immune suppressive cells in a murine model for mesthelioma. We selected 
registrated agents, to make research translational for future clinical immunotherapy 
studies. CHAPTER 6 demonstrates that treatment with metronomic cyclophosphamide 
leads to a reduction on Tregs in our murine model. These findings have led to the initiation 
of a new clinical phase I/II trial investigating the effectiveness of the combination of 
DC-based immunotherapy and metronomic cyclophosphamide in mesothelioma patients 
(preliminary data CHAPTER 7). In this final chapter, strategies to refine immunotherapy 
by targeting immune suppressive cells will be discussed. Furthermore, suggestions for 
further refinement of this approach are given.
8. Overview of the experimental work that was performed
8.1. Dendritic cell-based immunotherapy in mesothelioma patients
Ten patients were treated with standard chemotherapy followed by three vaccinations 
of autologous tumour lysate-loaded monocyte-derived dendritic cells (DCs), each dose 
consisting of 50x106 clinical-grade cells. Chemotherapy was given prior to DC vaccination 
in order to reduce tumour load, thereby potentially augmenting the efficacy of the 
vaccination as was earlier found in mice (1).
 Autologous tumour lysate priming strategies for DC loading was chosen to provide the 
full antigenic repertoire of the tumour and, particularly, unique individual tumour antigens, 
which will theoretically decrease the ability of tumours to evade the immune response by 
down-regulation of a single antigen. Lysates were prepared from patient’s tumour material 
derived from pleural fluid or from tumour tissue obtained by thoracoscopy. Tumour cell 
lysates were generated by repeated freeze-thaw cycles and irradiation with 100 Gy. DCs 
could be cultured in sufficient amounts from monocytes isolated by elutriation of the 
leukapheresis product using GM-CSF and IL-4. After 5 days in culture, DCs were pulsed 
with autologous tumor lysate and the model antigen keyhole limpet hemocyanin (KLH). A 
cytokine cocktail of IL-1b, IL-6, TNF-a and PGE-2 induced the final maturation step (at day 
8). The morphology (>95% veiled cells) and phenotype of cultured cells as assessed by 
flowcytometry was consistent with mature DC (CHAPTER 3). 
 Autologous tumour lysate-pulsed DCs were intradermally and intravenously administrated 
in MM patients after cytoreductive therapy with chemotherapy. All 10 patients received the 
three planned vaccinations. The results showed that injection of DCs was well-tolerated 
without major toxicity, with the exception of low-grade flu-like symptoms: fever, rigors 
(chills), and a temporarily local skin reaction after DC injection (mild grade 1 or 2). 
Local accumulation of CD4+ and CD8+ T cells were found at the vaccination sites. Body 
temperature was increased in 9 (of 10) patients but did not exceed 39 °C, mainly after 
the second and third vaccination. No participants experienced rash or lymphadenopathy 
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or developed any clinical evidence of autoimmunity. Delayed-type hypersensitivity (DTH) 
skintest and strong antibody immune responses (IgM and IgG) on the surrogate marker 
KLH were seen in all patients indicating that immune responses were generated. CT scans 
and X-rays from 3 patients revealed small to substantial regressions of the tumour during 
the DC treatment. Importantly, distinct anti-tumour activity against autologous tumour 
cells in the blood of 4 out of 6 patients was induced by the vaccinations. Although results 
are promising, further refinement of this therapeutic approach is recommended to improve 
clinical outcome. It has been suggested that tumour-related inflammation is one of the 
main reasons for immunotherapy failure. Since immune suppressive cells, recruited by 
tumour-derived factors inhibit the anti-tumour response and can induce T cell tolerance 
(2-5).   
  
8.2. Targeting immune suppressive cells
Regulation of the immune system is under control of immune regulatory cells, including 
myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs) (6-8). Besides, 
tumour-associated macrophages (TAMs) play a dominant role in tumour-microenvironments, 
facilitating angiogenesis, tumour-growth, metastasis and immune suppression (9). These 
cells are actively recruited and supported in their function by factors produced within the 
tumour microenvironment. In order to successfully influence these cells, it is important to 
determine which factors are critical for the recruitment and function of these cell types. 
        
8.3. Myeloid-derived suppressor cells
MDSC consist of a heterogeneous group of myeloid cells. These cells are not present in the 
blood circulation under normal conditions. However, under pathogenic conditions these 
cells can accumulate rapidly, leading to elevated levels in the peripheral blood, lymphoid 
organs and the affected tissue (6, 10). In tumour-bearing mice, this increase can rise 
to a percentages of >30% of all splenocytes (CHAPTER 4). MDSC are characterized by 
the expression of immature myeloid markers and mature myeloid cell markers, but more 
importantly, they are defined by their high arginase-1 activity, their ability to produce 
nitric oxide (NO) and reactive oxygen species (ROS). Production of the radicals leads to the 
inhibition of T cell proliferation, T cell apoptosis and the downregulation of the z-chain of 
the T cell receptor (11). The downregulation of the T cell receptor mainly takes place in the 
lymphoid organs and has been described as the most important factor in the induction of 
T cell tolerance. This mechanism is unfavourable for immunotherapy approaches, because 
it causes disfunction of cytotoxic T cells in an antigen specific manner. In contrast, the 
inhibition of T cell proliferation and the induction of T cell apoptosis is an antigen non-
specific way takes place at the tumour site (3, 6).  
 Investigations on MDSC function related to tumour-derived factors led to the 
understanding that in both inhibitory processes, ROS production and NO production, are 
depending on tumour-derived prostaglandin E2 (PGE2). The inducible enzyme cyclo-
oxygenase 2 (COX-2) is required for the synthesis of PGE2 (12). Several investigations 
showed that PGE2 is produced by many tumour types and that the high levels of COX-2 
and PGE2 correlate with decreased survival (13-16). The synthesis of PGE2 can be blocked 
by the inhibition of the COX-2 enzyme by using selective COX-2 inhibitors (e.g. Celecoxib 
(Celebrex®)). Via dietary administration of celecoxib in a murine mesothelioma model we 
were able to show that celecoxib blocks the production of tumour-derived PGE2, resulting 
in reduced activity of MDSC. Besides, our data provides evidence that celecoxib treatment 
not only reduced the function of MDSC but also their number in tumour bearing mice. 
Combining celecoxib treatment with DC-based immunotherapy improved the induced anti-
tumour response. Since ROS production has been described to be the main factor in 
the induction of immune tolerance, we analyzed the effect of COX-2 treatment on ROS 
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production by MDSC. Analyzing different subsets of MDSC revealed that treatment with a 
selective COX-2 inhibitor reduced the ROS production by all subsets (CHAPTER 4). 
 Another approach to target MDSC might be via inhibition of recruitment factors. Vascular 
endothelial growth factor (VEGF) has been reported to be an important factor leading to 
MDSC expansion (3). Therefore the inhibition of VEGF by selective VEGF-inhibitors is 
an interesting approach to modulate MDSC. The selective VEGF-inhibitor Bevacizumab 
(Avastin) is an interesting candidate in combination with DC-based immunotherapy to 
reduce the number and / or modulate the function of MDSC. 
  
8.4. Tumour-associated macrophages
Extensive research has been performed on the role of TAMs during tumour progression. 
TAMs play various roles in several processes facilitating tumour growth and tumour 
spread. Analyzing tumour tissues and pleural effusions of mesothelioma patients revealed 
that macrophages are present in high numbers. Besides, several clinical studies showed 
that there is a clear correlation between the number of tumour infiltrating macrophages 
and survival (18-21). To determine the effects of TAMs in relation to tumour growth, 
experiments were performed where macrophages were depleted using depleting liposomes 
(liposome-encaptured clodronate). Depletion of macrophages totally abolished tumour 
outgrowth. Therefore, targeting macrophages seems a promising tool to inhibit tumour 
progression; however liposome-encaptured clodronate is not applicable with DC-based 
immunotherapy. Liposomes are taken up by phagocytic cells and after the degradation of 
the liposome, clodronate is released inside the cell. Interference with intracellular cyclic 
AMP metabolism leads to apoptosis of these cells (22). Since DCs are also capable of 
phagocytosis, treatment with these liposome-encaptured clodronate also leads to the 
depletion of DCs. 
 Although, it is evident that TAMs play a crucial role during tumour progression, no 
commercial agents are available that specifically target macrophages. Since Non-N-containing 
bisphosphonates have shown to interact with cell metabolism these bisphosphonates have 
been proposed as clinical applicable agent to target cells. Several studies revealed that 
prophylactic treatment with bisphosphonates prevents metastasis. In addition, a recent 
study by Gnant et al. showed that treatment the N-containing bisphosphonate, zoledronic 
acid (Zometa), prolongs disease-free survival. Therefore, zoledronic acid (ZA) has been 
proposed as a new anti-cancer drug; however the exact mechanism by which ZA prevents 
tumour progression remains unclear (23). As treatment with ZA also influences cytokine, 
chemokine and growth-factor levels and reduces angiogenesis within tumours, it became 
more distinct that ZA may have an immune modulating effect on macrophages. For this 
reason we investigated if treatment with ZA affects the differentiation and function of 
TAMs in tumour bearing mice. 
 To determine the effect of ZA on macrophage function and differentiation, macrophages 
were investigated in vitro as well as in vivo. Although it was found that ZA had an inhibitory 
effect on macrophages differentiation and polarization, no significant improvement of 
survival was observed. Several explanations were proposed. One of the most striking 
observations during the experiments was that treatment with ZA led to an increase 
in immature myeloid cells because of inhibition of differentiation. These cells were 
characterized by an MDSC-like phenotype. As reported previously, these cells suppress 
anti-tumour activity and contribute to tumour progression. It was suggested that the 
decrease in TAMs was correlated with an increase in immature myeloid cells, since it 
was found that ZA inhibits myeloid differentiation in vitro resulting in a higher number 
of immature myeloid cells after 6 days of culture. Most studies on the effect of ZA on 
survival were investigated in tumour models with high metastatic rates. As TAMs play an 
important role in tumour metastasis, ZA may be beneficial in these tumour types where 
metastasis is the cause of death. Although ZA leads to a reduction in TAMs and affect the 
phenotype of macrophages, refining immunotherapy by the addition of single treatment 
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with ZA is believed to be insufficient (CHAPTER 5). Therefore, future studies will show if 
the combinating ZA with celecoxib holds more promise, since this approach might target 
both TAMs as well as MDSC. 
 Recently, Yondelis (Trabectedin) was reported as a potent agent to target macrophages, 
however severe side effects have been observed in a majority of patients and the cytotoxic 
character of the drug may interfere with the immunotherapy vaccine approach (24-25). 
Therefore, this is not an agent of first choice. Another approach to target TAMs may be via 
modulation of macrophage polarization or inhibition of factors linked to TAM recruitment. 
As hypoxia within tumours leads to the adaptation of TAMs, tumour-hypoxia has been 
proposed as a target to affect TAM accumulation. Hypoxia leads to the induction of hypoxia-
inducible factor (HIF)-1a which plays a critical role in the polarization and homing of TAMs 
(26). Recent, studies have shown that targeting of HIF-1 activity may disrupt the HIF-1/
CXCR4 pathway and therefore affect the accumulation of TAMs (27). Chemokines and 
chemokine receptors are also targets to control macrophage recruitment and infiltration. 
MCP-1/CCL2 has been proposed as most promising in this approach (28). 
 Furthermore, influencing the production of soluble factors by macrophages has been 
suggested as therapeutic targets. Since TAMs contribute to various processes during 
tumour development via production of soluble factors, specific inhibition of these products 
may also slow down tumour progression (4, 29). In this prospective, changing the balance 
from a M2 polarized macrophage to a M1 phenotype is most challenging (30). However, 
shifting this balance leads to certain difficulties, since the polarization is caused by 
defective NFkB activation. Restoration of the NFkB activation restored M1 inflammation 
and intra-tumoural cytotoxicity leading to the rejection of solid tumours in murine models 
(31). However, at this moment no clinical registered agents are available which specifically 
inhibit TAM recruitment or restore NFkB activation, making translation to the clinic more 
difficult.
 
8.5. Regulatory T cells
Tregs is a subset of CD4+CD25+ T cells that are characterized by the expression of 
FoxP3. In the normal situation Tregs are present in blood, bone marrow and in lymphoid 
organs. They play a crucial role in controlling the immune system. Especially in protection 
against auto reactive T cells by suppressing cytotoxic T cell function. However, during 
tumour development these cells expand by several factors and contribute to the induction 
of tolerance against tumour cells. Therefore, targeting Tregs has been proposed in the 
optimization of immunotherapy. 
 One proposed strategy is targeting CD25 via a CD25-specific depleting antibody (PC61). 
In 2006, Hegmans et al. showed that depletion of Tregs by PC61 (CD25 depleting antibody) 
led to prolongation of survival in a murine model for mesothelioma. Though, the combination 
of the human CD25 depleting antibodies; basiliximab and daclizumab; was not successful 
in cancer immunotherapy (32). An engineered recombinant fusion protein of IL-2 and 
diphtheria toxin (denileukin diftitox [Ontak]) was investigated for Treg depletion, which 
seems to kill selectively lymphocytes expressing the IL-2 receptor. However, early human 
trials have not proven that this approach results in tumour regression because it also 
depleted antitumor effector cells (33-36). The combination of CD25 depleting antibodies 
with DC-based immunotherapy seems inapplicable. We investigated the effectiveness of 
another agent in the combination with immunotherapy in depleting Tregs.
 Cyclophosphamide (CTX [Endoxan®]) is a nitrogen mustard alkylating cytotoxic pro-
drug that can be used as an immune modulating agent in a dose depending manner (37-
46). Metronomic administration of CTX prevents the induction of Tregs and inhibits Treg 
function; nevertheless the mechanism is not fully understood. It has been proposed that 
Treg are more sensitive to apoptosis induced by CTX, since the levels of the enzyme activity 
of aldehyde dehydrogenases (ALDH) is very low in T cells (especially Treg) compared 
to other lymphocytes (47-48). CTX is metabolised in the liver to active forms. ALDH is 
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essential in converting the toxic metabolite of CTX into non-toxic isoforms. Besides, CTX 
decreases the expression of GITR and FoxP3 on Tregs, which is associated with reduction 
in suppressive function (49-53). We showed that the therapeutic combination of CTX with 
DC-based immunotherapy was effective in a murine model for mesothelioma. Metronomic 
administration of CTX led to a significant reduction of Tregs in the lymphoid organs and at 
the tumour site (CHAPTER 6). 
 Other possible approaches to reduce immunosuppression of Tregs is via CTLA-4 blockade 
(54-55), anti-GITR agonism (56), and vaccination against Foxp3 (57). IL-7 administration 
was shown to increase T cell numbers and decrease of the Treg fraction in humans (58), 
on the contrary, other reports have shown that IL-7 leads to the development of Tregs (59-
60). Though, most of these approaches are still topic of research. Moreover, the results on 
the combination treatment of CTX and DC-based immunotherapy possess best translational 
opportunity, since low-doses CTX has been studied extensively and usage was found to be 
save and feasible in patients. Therefore, a new trial was initiated aiming at depleting Tregs 
using metronomic CTX in combination with DC-based immunotherapy as a multimodality 
treatment of residual tumour deposits following chemotherapy in mesothelioma patients 
(CHAPTER 7 (preliminary results)).
 
8.6. Main findings emerging from the experimental work
Administration of tumour lysate-pulsed dendritic cell vaccines in mesothelioma patients 
is safe and feasible (CHAPTER 3)
Dendritic cells pulsed with autologous tumour lysate are capable of inducing 
immunological response to tumour cells (CHAPTER 3) 
Local tumour growth leads to systemic alteration in the immune system affecting 
multiple organs like the bone marrow and lymphoid organs (CHAPTER 4,5,6)
Tumour-derived factors induce expansion and activation of immune suppressive cells 
(CHAPTER 4,5,6)     
MDSC can be divided in three subtypes; polymorph nuclear MDSC, mononuclear MDSC 
and Gr-1low MDSC in tumour bearing mice (CHAPTER 4)
Celecoxib reduces the number and suppressive function of MDSC, thereby improving 
immunotherapy (CHAPTER 4)
Zoledronic acid impairs myeloid differentiation towards TAMs in vitro and in vivo 
resulting in higher numbers of immature myeloid cells (CHAPTER 5)
Zoledronic acid affects the phenotype of macrophages leading to reduced TAM 
characteristics and lower expression of TAM-associated factors (CHAPTER 5)
Administration of metronomic cyclophosphamide reduces the number of Tregs in 
tumour-bearing mice (CHAPTER 6) 
Reducing Tregs improves cytotoxic T cell function and improves dendritic cell-based 
immunotherapy (CHAPTER 6)
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8.7. Composition of tumour environments in cancer patients
It is now thought that the effectiveness of immunotherapy is largely depending on 
suppressive environmental conditions of the patient. This environment is created by 
factors produced within the tumour microenvironment. These factors can either inhibit 
the anti-tumour response directly, but more importantly, induced hematopoiesis and 
recruitment of leukocytes capable of suppressing effector cells and enhancing tumour 
growth. As described in this thesis; MDSC, TAMs and Tregs are recruited by several factors 
and contribute to this tumour immune escape (2-5).
 Several studies attempt to reduce immune suppression by reducing the number and 
function of these immune suppressive cells. In order to do so, they focus on cell function 
and identification of recruitment factors. Immune suppressive cells can be targeted in 
various ways (Figure 1). However, as the numbers of reports on tumour microenvironments 
increases, it’s becoming more evident that the composition of the microenvironment 
differs between tumour types, but more strikingly may even differ between tumours 
from the same histological subtypes (61-63). Analyses of pleural effusions and tumour 
cell-lines of mesothelioma patients showed that they contain high levels of chemokines, 
growth factors and cytokines associated with recruitment and activation of several 
immune cells. In addition, it was shown that the expression of these factors reflects 
the presence of immunological cells within the tumour tissue (63). The expression level 
of these factors differed between patients. Same observations were done by Fukuyama 
et al. who determined the cytokine profile of 31 lung cancer cell-lines.and showed that 
high expression of GM-CSF and IL-8 is related to macrophages infiltration and enhanced 
angiogenesis in tumour tissue (61). Therefore, it can be hypothesized that variations 
in the composition of immune suppressive environments in cancer patients are largely 
depended on factors produced by tumour cells, and the composition of the environment 
within the tumour bearing host is a major factor influencing patient’s prognosis. 
 For example, high VEGF and COX-2 expression in squamous cell carcinoma and lung 
cancer correlates with poor survival (13, 64). Both factors were described as important 
factors in MDSC recruitment and function. A correlation was demonstrated between COX-2 
expression and arginase activity in MDSC and VEGF and the number of MDSC (3, 65-66). 
In this line, it can also be suggested that patients with tumours secreting low levels of GM-
CSF, M-CSF and CCL-2 have decreased metastatic potential and better survival prospects, 
since these tumours are less sufficient in recruiting and activating TAMs (29, 67-68). 
Though, more investigations are required to test these hypotheses. 
In other to test the hypotheses, we need to address various questions. For example, 
how can we identify and investigate immune suppressive cells in cancer patients and 
can patients be categorized based on these findings? And can we establish which factors 
and adjustments during tumourigenesis determine the difference in microenvironment 
composition? 
 In order to answer these questions, monitored of immune suppressive cells during 
treatment is required. By collecting blood and serum samples at different time points 
during follow up a base line level can be established. Variations in cell number should 
be correlated with cytokine- and chemokine profiles and may eventually show predictive 
value for disease progression. In addition, resection material and radiological findings 
The action of immune suppressive cells like MDSC and Tregs takes place at the 
tumour site and lymphoid organs leading to the induction of T cell tolerance and T cell 
apoptosis (CHAPTER 4,6)
Single treatment with agents targeting immune suppressive cells can prolong survival, 
however, these agents potentially synergize in combination with treatment approaches 
leading to activation of the immune system against tumour cells (CHAPTER 4,5,6)
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may contribute to our understanding on differences between local and systemic immune 
suppression and may hold predictive potential on tumour spread. Recent studies have 
shown that Tregs have value on predicting disease progression in several tumour types (69-
70). However, no single molecule or cell examined thus far within the tumour environment 
can serve as an absolutely independent indicator of patient survival. Therefore, it will be 
necessary to examine multiple tumour-associated cell populations in tandem with well-
defined pathological, clinical and genetic parameters to predict more accurately patient 
outcome (71). One of the challenges in these investigations will be the broad variety 
on therapeutic approaches, which eventually may interact with the immune system and 
therefore may cause difficulties in interpretation of the data. For example, recent studies 
have shown that certain types of chemotherapy affects MDSC more then other cells 
(72-73). Besides this, many patients use co-medication that might effect the immune 
system. 
To investigate differences in tumour behaviour related to tumour induced inflammation, 
murine models might be helpful. As cell-lines may differ in cytokine, chemokine and 
growth factor production, these differences may be reflected in the composition of the 
microenvironment. Recently, micro array data on two murine mesothelioma cell lines 
revealed that there is an enormous difference in gene expression. For example, AB1 cells 
produce mainly VEGF and PGE synthase, whereas AC29 tumour cells hardly secreted 
these factors. In contrast, AC29 expressed a range of chemokines and cytokines (e.g. 
TGF-b, MCP-1/CCL-2, MMP’s, IL-18), while production of these factors was diminished in 
AB1. Differences in secreted factors may influence tumour behaviour in vivo (preliminary 
data). 
As our understanding about the interactions between the immune system and tumour cells 
increases, it’s becoming more evident that differences in clinical presentation and prognosis 
may be closely related to variations in the constitution of tumour environments. At first 
instance, this new hallmark in tumour biology makes understanding of tumourigenesis and 
progression even more complex then previously believed. However, understanding these 
mechanisms is exceptionally important for refinement of novel treatment strategies, like 
immunotherapy. It can be assumed that those patients, with cancer-related inflammation 
enhancing MDSC expansion, will benefit from treatment with agents targeting MDSC 
(like celecoxib). Patients, with high numbers of Tregs, may benefit from treatment with 
metronomic cyclophosphamide.
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Figure 1. Targeting immune suppressive cells: Immune suppressive cells are localized in the tumour 
microenvironment as well as systemically, in tumour bearing hosts. These cells contribute to tumour 
progression and reduce the effectiveness of novel therapeutic approaches, like immunotherapy. Immune 
suppressive cells can be targeted in various ways. Firstly, targeting tumour cells by itself might eventually 
influence the composition of the microenvironment, as different therapeutic agents may selectively deplete 
tumour cells secreting certain factors (1). Secondly, neutralizing recruitment factors may also bring suppressor 
cell recruitment and differentiation to a hold (2). Other applicable approaches target immune suppressive 
cells directly by killing of these cells or inhibiting their cell function (3). Additionally, influencing suppressor 
cell function can be attempted by neutralization of suppressor cell stimulating factors (4). Finally, the effect 
of immune suppression can be abolished by eradicating of products produced by immune suppressive cells 
(5). 
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8.8. Clinical consequences and recommendation for refinement of dendritic-cell 
based immunotherapy   
This thesis reports on DC-based immunotherapy in mesothelioma and investigates 
approaches for refinement. We showed that the administration of clinical-grade dendritic 
cell vaccines in mesothelioma patients is safe and feasible. In addition, we demonstrated 
that an anti-tumour response against mesothelioma can be measured using this approach. 
Though, to reach full therapeutic potential, refinement of the strategy was recommended. 
In this thesis we determined the efficacy of several strategies to target immune suppressive 
cells. These cells were targeted with clinical applicable agents. In our murine model for 
malignant mesothelioma targeting these cells improved the survival and clinical out-come 
of immunotherapy. Significant challenges exist in refining immune therapy by determining 
the optimal combination of agents to abolish the tumour-derived environment inhibiting 
anti tumour responses. In order to do so, we should not focus on tumour types (and 
subtypes), but focus on individual patient characteristics. Cytokine-, chemokine-, and 
growth factor-profiles need to be analyzed in large cohorts of patients in order to provide 
information on immune cells that are present in the tumour tissue and the lymphoid 
organs.
 To make DC-based immunotherapy accessible for a larger group of mesothelioma 
patients, exclusion based on insufficiency of tumour material needs to be challenged. 
We demonstrated that pulsing DCs with autologious tumour material is a safe and 
feasible method to generate an immune response. However, this approach has a major 
disadvantage. The quality and quantity of the obtained autologous tumour material (for 
loading the dendritic cells) of most mesothelioma patients was insufficient for participating 
in the study. For ethical reasons, extra tumour material is not collected from patients 
without medical need. Also patients who had a mechanical or chemical pleurodesis or 
receiving chemotherapy are excluded because of the absence of tumour material for 
dendritic cell-loading. This major impediment introduced a substantial bias in patient 
selection and inclusion, making the interpretation of the performed study difficult. In 
such cases, preparations from other persons’ tumours of the same type might be used 
to pulse the autologous DCs in vitro, hypothesizing that common mesothelioma antigens 
may be expressed between malignant mesothelioma individuals. The use of allogeneic 
mesothelioma cell lines as antigen source is advantageous in providing a simpler and 
more standardized method of delivering a optimized and broad antigenic repertoire of 
potential tumour associated antigens for dendritic cell pulsing. There are obvious many 
clinical, scientific and economic advantages to develop such an allogeneic approach in DC-
based immunotherapy. In order to test if this approach is safe and leads to the generation 
of an anti-tumour response we will test this in a murine model. Autologous dendritic 
cells will be pulsed with different sources of allogeneic tumour cell derivatives generated 
from well-characterized mouse mesothelioma cell lines. The phenotype and activity of the 
dendritic cells after pulsing will be determined in vitro. Also the safety, immune responses 
and clinical activity in tumour-bearing mice will be studied following treatment with DC 
loaded with allogeneic tumour cell derivatives. Besides the optimal source of tumour cell 
derivatives, methods to increase the immunogenicity and further enrichment by protein 
fractionation will be investigated. 
 If shown safe and effective in animal models, we want to translate these findings to a 
clinical-trial with the intention to open up exciting new options to broaden the applicability 
for DC-based immunotherapy in the clinic. This would give a new prospective for the 
future to treat more mesothelioma patients with an optimized and standardized approach. 
It could make large multi centre trials possible that are urgently needed for the essential 
evaluation of the efficacy of dendritic cell-based immunotherapy.
Another intriguing future perspective for allogeneic loading of autologous DCs might 
be as prophylactic vaccine in individuals at risk of mesothelioma, in particular persons 
occupationally exposed to high amounts of asbestos fibres (e.g. workers at shipbuilding 
plants or industrial plants) or individuals expressing high levels of SMRP (MesoMark; 
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www.fdi.com/mesomark) without symptoms of disease. This cancer immunoprevention 
is currently of major interest in cancer research, however, it is far from clinic and several 
questions need to be answered through translational research before progressing into clinical 
trials (74-78). Nevertheless, if early therapeutic trials using DCs loaded with allogeneic 
material elicit significant immune responses with satisfying safety and toxicity results, first 
steps could be made in a preventive setting for mesothelioma. This is attractive approach 
because (I) there is clear group of individuals at risks, and (II) preneoplastic lesions caused 
by asbestos fibres are more sensitive to immune destruction than established tumours 
because they are smaller and less immunosuppressive. This was confirmed in mouse 
studies where DC-based immunotherapy was more effective in mice with smaller tumour 
loads (78), and (III) DC-based immunotherapy can induce long-term protective memory 
with no side effects (79). Prophylactic vaccination worked exceptionally well in case of 
infectious diseases. Also the success of the prophylactic cancer vaccine that immunizes 
against human papilloma virus and protects against cervical cancer has reinforced that 
prevention is better than therapy during disease (80-81). The prophylactic application of 
allogeneic approaches could be continuation on the long term.
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Mesothelioom
Mesothelioom; beter bekent als asbestkanker of borstvlieskanker; is een ernstige vorm van 
kanker. 80% van de patiënten overlijdt binnen een jaar na vaststellen van de ziekte. De 
oorzaak van mesothelioom is in veel gevallen te wijten aan asbestblootstelling. Asbest vezels 
kunnen diep in de longen terecht komen en daar na jaren van irritatie kanker veroorzaken. 
Mensen die aan mesothelioom lijden presenteren zich vaak bij de arts met klachten van 
kortademigheid, gewichtsverlies en/of pijn aan de borstkas. De kortademigheid wordt 
in veel gevallen veroorzaakt door een ophoping van vocht in de borstholte (tussen de 
longvliezen), die ontstaat als reactie op irritatie door de groeiende kanker. Dit vocht wordt 
in de meeste gevallen weg gehaald en onderzocht. De aanwezigheid van kankercellen 
in het vocht (en eventueel biopt-materiaal) in combinatie met asbst blootstelling in het 
verleden leidt in veel gevallen tot de diagnose mesothelioom. 
Hoewel het reeds lange tijd bekent is dat mesothelioom wordt veroorzaakt door de 
inademing van asbest vezels, heeft het jaren geduurd voordat het gebruik van asbest 
verboden werd. In Nederland is dit verbod sinds 1993 van kracht, maar toch zijn er nog 
veel landen waar het gebruik van asbest niet verboden is. In China, Rusland en India 
en Thailand wordt asbest nog op grote schaal gebruikt. Ook de productie van asbest-
bevattende materialen is nog altijd niet gestopt. Canada is een van de landen waar 
nog actief asbest wordt gewonnen uit asbestmijnen. Vanwege het economisch belang 
dat Canada hierbij heeft is het delven en het gebruik van asbest daar niet verboden. 
Dit asbest wordt vervolgens geëxporteerd naar derde wereld landen waar het materiaal 
gebruikt wordt voor de vervaardiging van asbestcement en golfplaten om huizen mee te 
bouwen. Ook worden er nog regelmatig grote asbestontdekkingen gedaan in gebouwen en 
schepen en komt asbest nog geregeld vrij bij brand en sloopwerkzaamheden. Daarnaast 
is recentelijk gebleken dat de blootstelling aan asbest gevaarlijker is dan voorheen werd 
verondersteld en dat de regelgeving rondom asbestverwijdering niet strikt nageleefd 
wordt. De verwachting is dat de incidentie van mesothelioom de komende decennia verder 
zal stijgen en zijn piek pas na 2025 zal bereiken. 
Momenteel is er geen goede behandeling voor mesothelioom. In de meeste gevallen 
worden patiënten behandeld met chemotherapie en/of operatie, maar beide behandelingen 
worden slechts gegeven om ziektesymptomen te verlichten en leiden niet tot genezing. 
Om deze reden is het van groot belang dat er nieuw behandelmethodes ontwikkeld 
worden voor deze vorm van kanker. Een van de behandelstrategieën waar momenteel 
veel belangstelling voor is, is immunotherapie.
Dendritische cel-immunotherapie
Immunotherapie heeft als doel de natuurlijke afweerreactie weer op gang te brengen. 
Dit kan op verschillende manieren, maar een van de methodes die momenteel veel 
belangstelling trekt is de dendritische cel-immunotherapie.
Dendritische cellen zijn heel goed in staat het afweersysteem op gang te brengen tegen 
“vreemde stoffen”, zoals bacteriën en virussen, maar daarnaast spelen ze ook een 
belangrijke rol in de vroege detectie van kankercellen. Door fragmenten van kankercellen 
aan lymfocyten te presenteren, kunnen deze cellen kankercellen herkennen als “vreemde” 
cellen en ze in een vroeg stadium opruimen. In veel gevallen zal dit er toe leiden dat 
kankercellen nooit volledig tot een klinisch observeerbare vorm uitgroeien en zullen 
mensen hier nooit klachten van ondervinden. Maar in sommige gevallen krijgt het lichaam 
niet alle kankercellen geëlimineerd en kunnen tumoren uitgroeien tot kanker. Dendritische 
cellen kunnen dan gebruikt worden om de afweerreactie opnieuw op gang te helpen.
Dendritische cellen kunnen in grote hoeveelheden buiten het lichaam gekweekt worden 
uit witte bloedcellen (monocyten). Deze cellen kunnen onder optimale omstandigheden 
in kontakt gebracht worden met gefragmenteerde kankercellen (lysaat). Dit lysaat kan 
door dendritische cellen opgenomen worden, wat dendritische cellen in staat stelt een 
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specifieke afweer reactie te veroorzaken. 
Dendritische cel-immunotherapie in mesothelioom patiënten
Nadat gebleken was dat immunotherapie met dendritische cellen tot goede resultaten leidde 
in een muismodel voor mesothelioom, zijn we in 2005 begonnen met een klinische studie 
waarin tien mesothelioom patiënten behandeld zijn met dendritische cellen opgeladen 
met autoloog tumor lysaat na chemotherapie (8-10 weken na de laatste chemotherapie).
Uit deze studie is gebleken dat het veilig is patiënten op deze manier te behandelen. Er 
traden geen onverwachte bijwerkingen op en er waren geen tekenen van auto-immuniteit. 
Daarnaast was er na drie vaccinaties in alle patiënten een afweerreactie meetbaar in het 
bloed tegen het model-antigeen keyhole limpet hemocyanin (KLH). KLH is een antigeen 
waar mensen van nature niet mee in aanraking komen en daarom hebben mensen geen 
antilichamen tegen dit antigen in hun bloed. KLH wordt tijdens de dendritische cel kweek 
samen met het lysaat aan de dendritische cellen toegevoegd. Op deze manier kunnen 
dendritische cellen dus een afweerreactie teweeg brengen tegen KLH. Hieruit is af te 
leiden dat de dendritische cellen functioneel waren en na teruggave instaat zijn gebleken 
lymfocyten te activeren. Daarnaast werd er in 4 van de 6 geteste patiënten een directe 
afweerreactie tegen kankercellen gevonden en was er bij enkele patiënten een verkleining 
van de tumormassa zichtbaar op CT-scans. 
Ondanks dat deze resultaten erg hoopgevend waren, waren er aanwijzingen dat het 
noodzakelijk was de therapie te verfijnen. Een van de belangrijkste oorzaken die genoemd 
worden voor de tegenvallende therapeutische effecten van immunotherapie is de 
aanwezigheid van immuunsuppressieve cellen in patiënten met uitgebreide kwaadaardige 
ziekten. Om immunotherapie in een klinische studie te kunnen verbeteren is er gezocht naar 
medicatie die te combineren is met immunotherapie en tegelijkertijd het afweersysteem 
zo kan beïnvloeden dat de functie en het aantal immuun suppressieve cellen afneemt. De 
effectiviteit van deze medicijnen in combinatie met immunotherapie werd eerst onderzocht 
in een preklinisch model.
Er spelen drie celtypes een belangrijke rol in het immuunsuppressieve milieu rond 
kanker; myeloide suppressor cellen (Myeloid-derived suppressor cells; MDSC), tumor-
geassocieerde macrofagen (TAMs) en regulatoire T lymfocyten (Tregs).
Myeloide suppressor cellen
Myeloide suppressor cellen (MDSC) komen onder normale omstandigheden niet in het 
lichaam voor, maar in het geval van stress (infectie, inflammatie, letsel of kankergroei) 
zijn ze in de lichaamscirculatie te vinden. Deze cellen komen uit de myeloide bloed lijn, 
dat wil zeggen dat deze witte bloedcellen ontstaan uit een voorlopercel die myeloblast 
heet. Uit dezelfde lijn komen ook de macrofagen en dendritische cellen voort. In het 
geval van stress komen deze myeloide cellen in de lichaamscirculatie. Hier kunnen ze de 
afweerreactie onderdrukken. Vanwege deze eigenschap zijn deze cellen beter bekend als 
MDSC.
MDSC kunnen de afweerreactie tegen kankercellen op verschillende manieren remmen. Ze 
kunnen dit doen rond de tumor en in de lymfeklier. Hier produceren ze een zuurstof radicaal 
dat er voor zorgt dat de afweercellen die in actie gekomen zijn tegen de kankercellen 
beschadigd raken en dood gaan. In de lymfeklieren kunnen MDSC de afweerreactie 
belemmeren door een zuurstof radicaal te maken die er voor zorgt dat de witte bloedcellen; 
die geprogrammeerd zijn om kankercellen aan te vallen; hun programmering verliezen. 
Hierdoor worden kankercellen niet meer door het afweersysteem herkend en dooft de 
afweerreactie tegen kankercellen uit. Naast hun suppressieve rol hebben MDSC ook het 
vermogen om; vanuit hun onrijpe karakter; verder uit te rijpen naar macrofagen die een 
belangrijke rol hebben in de progressie van kanker. 
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Voor de productie van radicalen zijn MDSC afhankelijk van prostaglandinen (prostaglandinen 
zijn hormoonachtige stoffen die op lokaal niveau betrokken zijn bij het reguleren van 
fysiologische processen). Prostaglandine E2 dat door kankercellen gemaakt kan worden, 
beïnvloedt de functie van MDSC het sterkst. In de productie van prostaglandinen is het 
enzym cyclo-oxygenase-2 (COX-2) van cruciaal belang. De activiteit van dit enzym is te 
remmen met COX-2 remmers. Om te onderzoeken of behandeling met de selectieve COX-
2-remmer; celecoxib; het aantal en de functie van MDSC beïnvloed, werden muizen in het 
mesothelioom model behandeld met celecoxib in combinatie met immunotherapie. Hieruit 
blijkt dat de muizen die met de combinatie van celecoxib en immunotherapie behandeld 
werden, significant langer leefden en dat deze overlevingswinst gepaard ging met een 
aanhoudende afweerreactie tegen kankercellen. Daarnaast nam het aantal en de functie 
van MDSC af. MDSC van muizen die met celecoxib behandeld werden, waren minder goed 
in staat zuurstof radicalen te produceren. De combinatie van celecoxib en immunotherapie 
lijkt een effectieve manier om immuunsuppressie die veroorzaakt wordt door MDSC is 
verminderen.
Tumor-geassocieerde macrofagen
Macrofagen hebben een belangrijke taak in het lichaam. In de normale situatie zijn ze 
betrokken bij de aangeboren afweer tegen ziekteverwekkers (inflammatoire macrofagen). 
Maar daarnaast zijn er ook macrofagen die betrokken zijn bij “herstel werkzaamheden” 
(alternatief geactiveerde macrofagen). Deze macrofagen zijn betrokken bij het ombouwen 
van weefsels. Zij zorgen er voor dat er nieuwe bloedvaten aangelegd worden, ruimen oude 
cellen (celfragmenten) op en produceren stoffen die andere immuuncellen aantrekken die 
nodig zijn bij de weefselombouw. 
Kankercellen maken van deze eigenschappen van macrofagen gebruik om bloedvaten te 
generen en weefsel beter toegankelijk te maken voor verdere doorgroei. Daarnaast zorgen 
de stoffen die macrofagen maken ook voor de aantrekking van MDSC, die vervolgens als 
bron kunnen dienen voor nieuwe macrofagen. Maar macrofagen kunnen ook de afweer 
reactie negatief beïnvloeden. Net als MDSC kunnen macrofagen zuurstof radicalen maken 
die celdood van immuun cellen tot gevolg heeft. Daarnaast produceren ze stoffen die 
direct een negatieve invloed hebben op de functie van de immuun cellen. 
Het is al geruime tijd bekend dat macrofagen een belangrijke rol spelen in het faciliteren 
van kankergroei. Toch zijn er weinig middelen beschreven die de aantrekking en de functie 
van tumor-geassocieerde macrofagen remt. Recentelijk is gebleken dan bisfosfonaten de 
potentie hebben het afweersysteem te modificeren. Bisfosfonaten worden in de dagelijkse 
praktijk gebruikt ter preventie van botontkalking (osteoporose) en ter preventie van 
breuken door uitzaaiingen van kwaadaardige ziekten naar het bot. Preventieve behandeling 
van kanker patiënten met deze middelen leverde nieuwe inzichten op. Uit grote studies 
bleek dat vroegtijdig starten met bisfosfonaten niet alleen het aantal botbreuken door 
uitzaaiingen verminderde, maar dat ook het aantal uitzaaiingen afnam. Dit onverwachte 
effect is moeilijk te verklaren en heeft tot veel discussie geleid. Uit deze discussies kwam 
als mogelijke verklaring naar voren, dat bisfosfonaten mogelijk een gunstig effect kunnen 
hebben op het immuunsysteem. In deze discussie is er veel aandacht voor een nieuwe 
bisfosfonaat; zoledroninezuur (Zometa). 
Om het immuun modulerende effect van zoledroninezuur op macrofagen te onderzoeken 
werden macrofagen gekweekt in het laboratorium. De toevoeging van zoledroninezuur 
aan deze kweek had een vermindering van het aantal macrofagen tot gevolg, als een 
consequentie hiervan blijf het aantal immature myeloide cellen hoog. Daarnaast hadden deze 
macrofagen minder tumor-geassocieerde karakteristieken. Toch leverde de behandeling 
van muizen in het mesothelioom model met zoledroninezuur niet de gewenste resultaten. 
Hoewel er ook een afname van het aantal macrofagen detecteerbaar was in muizen die 
met zoledroninezuur behandeld werden leverde de behandeling geen overlevingswinst op. 
Er zijn verschillende verklaringen voor deze bevinding. Zo kan het zijn dat de afname in 
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macrofagen niet opweegt tegen de stijging van de immature myeloide cellen met MDSC 
kenmerken. Daarnaast kan het ook zo zijn dat de effectiviteit van zoledroninezuur in een 
muis model minder effectief is vanwege kinetische eigenschappen van het medicament. Uit 
de experimenten hebben we geconcludeerd dat single therapie met zoledroninezuur geen 
goede manier is om tumor-geassocieerde macrofagen te beïnvloeden in mesothelioom. 
Mogelijk is een gecombineerde behandeling van zoledroninezuur met andere medicijnen 
(zoals bijv. celecoxib) zinvoller. Meer studies zijn nodig om hier duidelijkheid over te 
verschaffen. Momenteel zijn er weinig alternatieven, om macrofagen te beïnvloeden. 
Yondelis (Trabectedin) wordt onderzocht maar lijkt geen geschikt middel voor de combinatie 
met immunotherapie vanwege ernstige bijwerken. Daarnaast wordt er onderzocht of de 
aantrekking van macrofagen voorkomen kan worden door stoffen weg te vangen die een 
rol spelen in de stijging van macrofagen.
Regulatoire T cellen
Het derde celtype die een belangrijke functie vervuld in de immuun escape zijn regulatoire T 
cellen (Tregs). Tregs komen normaal gesproken in een beperkte hoeveelheid in het lichaam 
voor. Ze zorgen er voor dat het afweersysteem niet opgang komt tegen lichaamseigen 
antigenen. Zo voorkomen ze auto-immuun ziekten en reguleren ze de immuunresponse.
Tregs komen verhoogd voor in het bloed, de lymfklieren en rond de tumor bij mesothelioom 
patiënten. Deze verhoging heeft een ongunstig effect op de afweerreactie en daarom lijkt 
het reduceren van deze cellen een goede strategie om immunotherapie te verbeteren. In 
2006 heeft Hegmans et al. beschreven dat de behandeling met PC61 een verlaging van 
het aantal Tregs gaf en dat deze verlaging een verbetering van de overleving tot gevolg 
had in een muis model voor mesothelioom. PC61 is een antilichaam dat bindt aan CD25, 
wat onderdeel is van de interleukine 2 receptor. Deze receptor komt voor op Tregs, maar 
daarnaast ook op geactiveerde B en T lymfocyten. De behandeling met dit depleterend 
antilichaam leverde een vermindering van het aantal Tregs op en een verbetering van de 
overleving. Maar omdat PC61 ook geactiveerde T en B lymfocyten kan verminderen en 
deze cellen juist nodig zijn om de kanker te bevechten, leek de combinatie van PC61 en 
immunotherapie niet geschikt. Daarnaast zijn de studies die met de humane variant van 
PC61 gedaan zijn niet zinvol gebleken. Daarom hebben we gezocht naar een middel dat 
Tregs kan verminderen en gebruikt kan worden voor klinische doeleinden (om de stap 
naar een eventuele klinische studie mogelijk te maken). Een middel wat hiervoor geschikt 
lijkt is cyclofosfamide (CTX [Endoxan®]).
Cyclofosfamide is een “pro-drug” met een alkalyserende werking. Het middel heeft een 
therapeutische toepassing als chemotherapeuticum in de behandeling van lymfomen, 
maar daarnaast wordt het tegenwoordig ook in lage dosering toegepast bij de behandeling 
van auto-immuunziekten. Hoewel het werkingsmechanisme niet goed bekent is, lijkt het 
middel een immuunmodulerende werking te hebben en in een lage dosis specifiek Tregs 
te kunnen verlagen. Om deze reden hebben we onderzocht of de behandeling van muizen 
met CTX in combinatie met immunotherapie zinvol was. Muizen werden behandeld met 
CTX in verschillende doseringsschema’s. Hieruit bleek dat continue behandeling met CTX 
in een lage dosis in combinatie met immunotherapie de beste resultaten liet zien. Het 
aantal Tregs nam significant af en de overleving verbeterde. 
Dit heeft er toe geleid dat we begin 2010 gestart zijn met een nieuwe klinische studie waarin 
mesothelioom patiënten nu behandeld worden met de combinatie van immunotherapie 
en een lage continue dosis van cyclofosfamide. We hopen deze studie eind 2011 af te 
ronden. In de tussen tijd zullen we onderzoeken of het mogelijk is om patiënten beter 
te karakteriseren op basis van immuunparameters om te bepalen welke combinatie 
van medicijnen in de toekomst het beste gegeven kunnen worden in combinatie met 
immunotherapie voor de behandeling van individuele patiënten. Daarnaast zullen we 
onderzoeken of het mogelijk is patiënt eigen dendritische cellen op te laden met lysaat van 
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mesothelioom cellijnen (mesothelioom cellen die in het laboratorium gekweekt kunnen 
worden), om gerandomiseerde klinische studies met grotere groepen patiënten mogelijk 
te maken. Op deze manier kan de werkzaamheid beter onderzocht worden en zullen in 
de verre toekomst mogelijk risicogroepen preventief ingeënt kunnen worden tegen deze 
vorm van kanker.
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motiverende kritieken, maakt je tot een co-promotor die veel promovendi zich zouden wensen.
De overige leden van de kleine en grote commissie: Prof. dr. B.N.M. Lambrecht, Prof. dr. L.H.J. Looijenga, Prof. 
dr. M. den Bakker, Prof. dr. C. Figdor en Prof. dr. J. van Meerbeeck wil ik bedanken voor het beoordelen van mijn 
proefschrift en het plaatsnemen in de commissie.
Mijn paranimfen: best Menno, hoewel we weinig experimenten samen gedaan hebben, ben je toch ook van 
doorslaggevend belang geweest bij de voltooiing van dit proefschrift. Promoveren op een lab valt niet altijd 
mee en daarom is steun vaak hard nodig. Als je die kan vinden bij iemand die op alle fronten eenzelfde kijk op 
de dingen lijkt te hebben, is dat een geluk dat je niet vaak tegen komt. Ik ben zelden iemand tegen gekomen 
die zo veel interesses heeft op allerlei gebieden en daar ook nog iets zinnigs over kan zeggen. Naast een 
goede collega ben je ook een goede vriend geworden.
Lieve Caroline, bij alles wat ik doe word ik door jou op de voet gevolgd. Samen hebben we de middelbare 
school, onze studie en coschappen doorlopen. Na je coschappen ben je naar Leiden gegaan en heb jij voor 
het andere orgaan in de thorax gekozen. Hoewel onze wegen dan nu splitsen, hoop ik dat ze in de toekomst 
weer samen komen en we ooit in hetzelfde ziekenhuis zullen werken. Maar ook als zus neem je in mijn leven 
natuurlijk een belangrijke plaats in. Op jouw onvoorwaardelijke steun kan ik altijd rekenen en ben daarom 
trots en blij dat je vandaag als paranimf naast me wilt staan. 
Margaretha Lambers: beste Margaretha, zonder jouw hulp bij de vele experimenten had het proefschrift 
nog wel even op zich laten wachten. Ik weet dat ik als promovendus met minimale lab ervaring niet altijd de 
meest makkelijke collega ben geweest om mee te werken. Zoals ik ook Joost al bedankte voor zijn geduld, wil 
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ik dat zeker bij jou nogmaals doen. Daarnaast wil ik je natuurlijk ook bedanken voor de gezellige tijd.
Alle collega’s van het lab: Anoek, Alex, Annemieke, Bregje, Charissa, Claudia, Corine, Femke, Hamida, 
Hermelijn, Hoyan, Ingrid, Joao, Karoline, Laurens, Leonie, Marjolein, Marthe, Monique, Mirjam, Nanda, Ntaleah, 
Odelia, Pieter-Fokko, Roel, Sanne, Tanja, Van, Wilma en Yelvi bedank ik voor de gezellige tijd. 
Alle collega’s uit het ziekenhuis: Alice Kars, Leon van der Toorn, Marlies Wijsenbeek, Robin Cornellissen, 
Robert Peric, Rob van Klaveren, Bernt van den Blink, Peter van Hal, Marleen Bakker, Menno van der Eerden, 
Henk Otten, de arts-assistenten groep, de dames van de polikliniek en alle verpleegkundigen op de afdeling 
wil ik bedanken voor het prettige contact in de afgelopen jaren.
Collega’s van andere afdelingen en uit andere ziekenhuizen: Hans Stoop (en andere oud-collega’s van 
LEPO), Gerben Schaaf (voor de ideeën uitwisseling), Meriam Grootes (en de andere medewerkers van de 
aferese afdeling), Anna de Goede en Arnold Vulto (voor hun bijdragen aan de klinische studie), Mick Heijsteeg, 
Rob Slingerland, Gert Verhoeven en Peter van Tilburg (voor hun motiverende enthousiasme, dat mij heeft doen 
besluiten verder te gaan in de longgeneeskunde), alle longartsen die hun patiënten doorverwezen hebben / 
deel hebben laten nemen aan het onderzoek (in het bijzonder de longartsen uit het Vlietland ziekenhuis, de 
longartsen uit het Albert Schweitzer ziekenhuis en de longartsen uit het Sint Franciscus Gasthuis en Judith de 
Herder uit het st. Antonius ziekenhuis).
De stichting asbestkanker: Graag wil ik de heren van de stichting asbestkanker (dhr. J.J.M van Rijckevorsel, 
drs. W.M.J. Schippers, prof.dr. A.H.N. Stollenwerck en mr. J. van de Ven) bedanken voor hun belangeloze inzet 
voor deze stichting. Zonder het geld dat door jullie ingezameld wordt, is continuïteit van het onderzoek niet 
te garanderen. Daarnaast wil ik in het bijzonder mijn waardering uitspreken voor dhr. J.J.M. v. Rijckevorsel; uw 
betrokkenheid is buitengewoon en bewonderenswaardig.
Daarnaast zijn er mensen die ik wil bedanken, omdat zij een belangrijke rol spelen in mijn leven en daarbij 
indirect ook een groot aandeel hebben gehad in het tot stand komen van dit proefschrift.
Thierry en Eelke: Lieve vader en moeder, zonder jullie had ik hier nooit gestaan. Hoewel jullie natuurlijk 
beiden een belangrijke rol hebben gespeeld in mijn ontwikkeling, wil ik mijn moeder in dit kader in het 
bijzonder bedanken. Zonder jouw hulp en steun had ik hier nooit gestaan. De wetenschap dat jullie er altijd 
voor mij zijn is erg belangrijk voor me. 
Mijn zussen: Lieve Roosje, jouw rol in mijn leven is groter dan je denkt. Mijn hele leven leef ik tussen jou 
en Caroline in. Jij haalde met gemak je gymnasium en rondde je studie met succes af en Caroline ging haar 
oudere zus op hoog tempo achterna. Ik kon daarom natuurlijk niet achterblijven. Voortgestuwd door jullie 
gedrevenheid en toewijding, ben ik dus ook hard gaan studeren om niet achterop te raken en jullie niet teleur 
te stellen. Ik ben trots op jullie en op hetgeen we met z’n drieën bereikt hebben. Bedankt voor jullie steun.
Mijn vrouw: Als laatste wil ik natuurlijk mijn vrouw Loesje bedanken; Lieve Loesje, achter elke man die iets 
presteert, staat een vrouw die motiveert. Met jou kan ik alles delen en je bent er altijd. Dit gegeven is voor 
mij erg belangrijk. Je bent de ideale vrouw om na een drukke dag werken bij thuis te komen. Op jou kan ik 
rekenen als het soms even tegen lijkt te zitten, maar ook op de momenten dat er wat te vieren valt. Bedankt 
voor je liefde en steun.
Rotterdam 8 December
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Het schilderij op de omslag van dit proefschrift is gemaakt door Thierry Veltman. Het werk verbeeldt 
het uitzicht op de Rotterdamse haven vanaf de 22ste verdieping van het faculteitsgebouw van 
het Erasmus MC, waar het laboratorium Longziekten gehuisvest is. Voor dit beeld is gekozen, 
omdat de haven in belangrijke rol heeft gespeeld bij de initiatie van het onderzoek naar 
asbestkanker in het Erasmus MC. In de jaren 60/70 is er veel scheepsbouw activiteit geweest in 
dit havengebied. Bij het bouwen van deze schepen is veel asbest gebruikt en zijn veel mensen 
aan deze kankerverwekkende stof blootgesteld gweest. Dit heeft er toe geleid dat de incidentie 
van het aantal mesothelioom patiënten in Rotterdam ver boven het landelijk gemiddelde ligt. 
Daarom is er in het verleden het initiatief genomen om een onderzoeksgroep op te richten die 
hun aandacht richten op het bevordering van de diagnostiek en behandeling van mesothelioom. 
Daartoe is in 1998 de Stichting Asbestkanker opgericht. De Stichting Asbestkanker werft 
fondsen die ten goede komen aan onderzoek waarmee versneld therapieën beschikbaar komen 
in de kliniek voor een betere behandeling van asbestkanker. Zonder hun financiële steun was 
het onderzoek niet mogelijk geweest. www.asbestkanker.com
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